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Obesity is a major contributor to the global burden of disease and is closely 
associated with the development of type II diabetes. Recent studies have 
demonstrated that increased circulating free fatty acid (FFA) levels may have 
detrimental effects on the diabetic heart. In this study, we hypothesized that with 
obesity and obesity-induced insulin resistance! type II diabetes, increased FFA supply 
decreases cardiac mitochondrial bioenergetic capacity. Furthermore, we also 
hypothesized that females possess innate cardioprotective programs that will result in 
enhanced bioenergetic capacity compared to males. We examined our hypothesis 
employing two rodent models i.e. a) a rat model of diet-induced obesity and b) a 
transgenic (leptin receptor deficient) mouse model of obesity-induced type II 
diabetes. For the diabetic mouse model, we determined cardiac mitochondrial 
respiratory function in an age-dependent (10-12, 18-20 and 55-56 weeks) and 
gender-dependent (male versus female) manner. 
We found impaired mitochondrial respiratory capacity in obese rats at baseline and 
when isolated mitochondria were stressed by anoxia-reoxygenation. We speculate 
that this may be due to reduced expression of mitochondrial respiratory chain 
complexes in the insulin resistant rat heart. For the mouse model of type II diabetes 
we found increased respiratory capacity at 10-12 weeks, thought to represent the 
stage of metabolic syndrome, with no evidence of oxygen wastage or reduction of 
respiratory capacity. However, 18-20 week-old obese mice were unable to increase 
respiratory capacity. We also found increased mitochondrial ultrastructural damage 
and intracellular lipid accumulation in 18-20 week-old diabetic mouse hearts. We 
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decreased FA oxidative capacity. 
We found interesting gender-dependent changes in younger female mice which 
showed enhanced protection when mitochondria were stressed by 
anoxia-reoxygenation. These data were paralleled by increased intracellular ATP 
levels, suggesting that young female mice possess increased mitochondrial 
bioenergetic capacity at baseline. Moreover, our electron microscope data suggest 
that the ultrastructure of male mitochondria is more disorganized when compared to 
female controls. However, the protective phenotype in females is abolished with 
obesity. Our data therefore suggest that female mice possess an innate 
cardioprotective program that enhances mitochondrial biogenetic capacity to protect 
the female heart against anoxic! ischemic stress. However, with the onset of 
obesity-induced type II diabetes this cardioprotective program is perturbed. 
Mitochondrial respiratory function and bioenergetic capacity is reduced in both male 
and female mice at 55·56 weeks. We suggest this is an age-dependent phenomenon 
and speculate that it may due to increased ROS production. In summary, this study 
highlights the significance of sustained biogenetic capacity to ensure an organism's 
survival. However, with obesity and obesity-induced type n diabetes this energetic 
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1. Epidemiology of Obesity 
Obesity is a chronic condition characterized by excessive body fat accumulation. Its 
underlying causes are multifactorial, resulting from interactions between genetics 
and environment 1 and include human factors e.g. metabolic, psychological, 
hormonal, social status, cultural habitats and modem lifestyle trends. The latter 
includes for e.g. increased consumption of energy-dense foods (high in saturated fat 
and sugars) and reduced energy expenditure (lack ofphysical activity). 2 
The incidence of obesity has reached global epidemic proportions, with estimates of 
more than a billion overweight adults and ~ 300,000 of these thought to be clinically 
obese. 3 Recently, the World Health Organization (WHO) ranked obesity in the top 
10 risks to human health worldwide including developed and developing nations. 3 A 
recent study reported that more than 56% of South African women are overweight! 
obese, thereby a major contributor to the local burden of disease. 4 Moreover, the 
prevalence of obesity is continuously rising and the incidence of childhood obesity 
has reached alarming proportions. 5 
Obesity is commonly assessed by using body mass index (BM!) as well as the 
abdominal girth! waist circumference and waist-to-hip ratio. 6,7 BM! is an assessment 
in relation to an individual's weight and height and is calculated as weight in 
kilograms (kg) divided by the square of height in meters (m2). BM! generally 
increases with age and is usually higher amongst middle-aged people. 7 The 
representation of overweight and obesity determined by different measurements is 





















Both waist circumferences and waist-to-hip ratio provide an independent prediction 
for weight-related health risk. For example, an individual with a high waist 
circumference is associated with an increased risk for high blood pressure, high 
cholesterol, type II diabetes and heart disease. 8 Furthermore, due to differences in 
ethnicity, waist circumference and! or waist-to-hip ratio is considered an improved 
measurement to predict the relative disease risk compared to BMl 9 For example, the 
BMI mean for the average African and Asian adult is 22-23 kg! m2 compared to 
25-27 kg! m2 for Europeans and North Africans. Although these criteria are generally 

















Table 1. Representation of the most widely used criteria to assess obesity 
Common obesity criteria Assessment 





Slight health risk 
High risk 





18.5 - 24.9 




Waist> 37 inches (~94 cm) 
Waist> 40 inches (~ 102 cm) 
Female 
Waist> 31 inches (~ 80 em) 






BMl of30 - 34.9 and 35 - 39.9 kg!lIi are classified as obesity classes 1 and 11, respectively. Extreme 

obesity is classified as obesity class III, where the BMl::: 40 kg! m1. 

Data modifiedfrom Centers for Disease Control and Prevention (CDC) and US National Heart, Lung, 

andBloodInstitute (NHLBJ). 6,7 

1.1. Lifestyle changes 
Modem-day individuals are continually striving for increased convenience in tenns 
of lifestyle. For example, societies are moving away from traditional foods and the 
intensive preparation ofmeals. In contrast, mass-produced processed foods (higher in 
fat, lower in fiber and micronutrients) are becoming cheaper thereby resulting in 











new era of sedentary living. For example, modern society has growing access to 
conveniences such as microwaves, internet, cars, remote-controlled television, 
computer games, etc. 10 Increased fat consumption and reduced physical activity are 
considered major factors contributing to increased rates of global obesity and the 
subsequent development oftype II diabetes (Table 2). II 
Table 2. Lifestyle factors promoting obesity 
Modem technologies: 
• Processed food, internet shopping 
Lifestyle changes: 
• Less time in supermarket or kitchen 
• Automated transportation • Less movement (by foot) to reach 
destinations 
• Television, computer games • Children play less outside, prefer 












2. Metabolic Syndrome 
High incidences of obesity have contributed to the increased global prevalence of 
metabolic syndrome and its associated complications. 12, 13 Several definitions and 
criteria for metabolic syndrome have been proposed to identify individuals who are 
at high risk of developing type II diabetes and cardiovascular disease (CVD). 
However~ at this stage consensus has not been reached. Currently, the most widely 
used definitions are a) the newly modified version from the International Diabetes 
Fedef8,tion (IDF) that takes into account differences in ethnicity, b) US National 
Cholesterol Education Program's Adult Treatment Panel III (NCEP: ATPIII) and c) 
WHO (Tables 3 and 4). 13,14 
Metabolic syndrome is a complex condition with a cluster ofmetabolic abnormalities, 
including insulin resistance~ impaired glucose tolerance (IGT) and lipid metabolism, 
abdominal obesity, dyslipidemia, hyperglycemia and hypertension. Moreover~ it is 














Table 3. Comparison of metabolic syndrome def"mitions from tbe International 
Diabetes Federation (IDF), US National Cbolesterol Education Program's Adult 
Treatment Panel m (NCEP: ATPIII) and World Healtb Organization (WHO) 
IDF,2004 BMI >30 kglm2 or waist circumference >85-94 cm (male); >80-90cm 
(female) (range with different ethnic specific cutoffs - Table 4) 
Plus 2 or more ofthe following: 
1. Dyslipidemia: triglycerides > 1. 7 mmollL. 
2. HDL <1.03 mmollL (male); <1.29 mmollL (female) or specific 
treatment for these lipid abnormalities. 
3. Hypertension: blood pressure> 130/85 mm Hg or treatment of 
previously diagnosed hypertension. 
4. Fasting plasma glucose ?:5.6 mmollL (subsequent oral glucose 
tolerance test is strongly recommended) or previously diagnosed 
type IT diabetes. 
NCEP:ATPm, Three or more ofthe following: 
2001 1. Central obesity: waist circumference> 1 02 cm (male); >88 cm 
(female). 
2. Dyslipidemia: trigIycerides?: 1.7 mmollL. 
I 3. HDL <1.0 mmollL (male); <1.3 mmollL (female). 
4. Hypertension: blood pressure ?:130/85 mm Hg or medication. 
5. Fasting plasma glucose ?:6.1 mmollL. 
I 
WHO, 1999 Diabetes! impaired fasting glycemia! impaired glucose tolerancel 
insulin resistance (hyperinsulinemia, euglycaemic clamp-glucose 
uptake in lowest 25%) 
Plus 2 or more ofthe following: 
1. Obesity: BMI >30 kglm2 or waist-to-hip ratio >0.9 (male); >0.85 
(female). 
2. Dyslipidemia: triglycerides ?:l. 7 mmollL. 
3. HDL <0.9 mmollL (male); <1.0 mmollL (female). 
4. Hypertension: blood pressure> 140/90 mm Hg. 
5. Microalbuminuria: albumin excretion >20 J.1gImin. 











Table 4. Waist circumference with different ethnic·specific cutoffs used for 
identification of metabolic syndrome 
Ethnic group Waist circumference (cm) 
Male Female 
Europeans, Sub-Saharan Africans 























3. Type II Diabetes 
The incidence of type II diabetes mellitus is a growing global phenomenon and 
represents a major threat to public health. 3 Epidemiological data published during 
2000 reported more than 1.7 million of diagnosed diabetics worldwide. The number 
of diagnosed diabetic patients in South Africa is currently estimated at ~ 800,000. 3,4 
Moreover, the WHO has projected that by 2030 ~ 1.3 million South Africans will be 
affected by this life-threatening disease (Table 5). 
Table 5. The global prevalence of diabetes 
Country 2000 2030 
Africa 





Eastern Mediterranean 15,188,000 35,941,000 
America 33,016,000 66,812,000 
Europe 33,332,000 47,973,000 
South East Asia 46,903,000 119,541,000 
Western Pacific 35,771,000 71,050,100 
Total 171,230,000 359,551,100 
Data obtained and modifiedfrom WHO. 16 
Available at: URL: Available at http://www.who.int/diabeteslJactslworldJigures/eniindexJ.html 
There are two types of diabetes i.e. Type I and Type II diabetes mellitus. Type I 
diabetes mellitus is also known as insulin-dependent diabetes mellitus (IDDM) i.e. in 
this condition the pancreas fails to secrete insulin. 12 Type II diabetes mellitus, the 
main focus of this project, is the most common form of diabetes and accounts for ~ 











non-insulin dependent diabetes (NIDDM). 17 It is a multifactorial.disease that occurs 
primarily in adults aged 35 - 64 years, and results from impaired insulin sensitivity 
with progression of IGT. With the increasing incidence of childhood obesity, type II 
diabetes can occur in obese children even before puberty. 2,18 
3.1. Type II diabetes aDd cardiovascular disease 
The risk of diabetic patients developing ischemic heart disease and acute myocardial 
infarction are greater compared to non-diabetic individuals. 19 Evidence suggests that 
metabolic syndrome and type II diabetes cluster with cardiovascular complications 
like atherosclerosis, coronary heart disease (CAD) and cardiomyopathy. 13,20,21 For 
example, CAD is currently the single leading cause of death for US patients with 
type II diabetes, resulting in ~ 500,000 deaths in 2002. 17,22 The incidence of total 
events from CAD increases steeply with age. Interestingly, the risk of males 
developing CAD is much higher and on average presents 10-15 years earlier 
compared to females (Table 6). 23, 24 This suggests that gender differences may 
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Table 6. Prevalence of CAD increases with age 
Age 














Data obtainedfrom Fordor et al. (2004). 24 
Since type II diabetes is the result of altered metabolism, I will now briefly review 
metabolism of the nonnaI heart before discussing altered metabolic pathways 
associated with the diabetic phenotype. 
3.2. Cardiac fuel substrate utilization 
The normal human heart requires an abundant supply of energy :::::: 3.5 - 5 kg of 
adenosine triphosphat  (ATP) to sustain its contractile function. 25 Glucose and fatty 
acids (FA) are the main fuels for the normal, postnatal mammalian heart. After 
uptake, fuel substrates are catabolized by intermediate metabolic pathways for 
energy production in mitochondria, the "power-houses" of the cell. However, 
substrate utilization by the heart is dynamic i.e. it has the capacity to select the most 
appropriate fuel substrate depending on the particular physiologic/ pathophysiologic 
context. For example, during conditions of oxygen lack (exercise, ischemia), cardiac 
glucose utilization is enhanced 25,26 Here, cardiac metabolic remodeling occurs since 











3.2.1. Glucose metabolism 
Glucose uptake from the bloodstream into cardiomyocytes is facilitated by glucose 
transporters (GLUTs). In the heart, two isoforms predominate Le. GLUT 1, the fetal 
isoforms, and GLUT 4 the insulin-responsive adult transporter. 25, 28 After uptake, 
glucose is rapidly phosphorylated to glucose-6-phosphate by hexokinase (HK). 
Subsequently, it is converted to fructose-6-phosphate which in tum is converted to 
fructose-I, 6-bisphosphate by phosphofructokinase (PFK), the rate-limiting enzyme 
of glycolysis (Fig. 1). 29 Excess glucose can be stored as glycogen and can be 
reconverted to glucose-6-phosphate if required. 30 Fructose-I, 6-bisphosphate is 
metabolized to pyruvate via several steps. 29 Pyruvate is transported into the 
mitochondrion where it is catabolized to acetyl coenzyme A (acetyl-CoA) by 
pyruvate dehydrogenase (pDH), the rate-limiting enzyme of glucose oxidation. 
However, under anaerobic conditions lactate is fonned from pyruvate. Acetyl-CoA 
produced from the oxidative decarboxylation ofpyruvate represents the link between 
glycolysis and the citrate acid cycle. Reducing equivalents (NADH and FADH2) 
from the citrate acid cycle subsequently enter the mitochondrial respiratory chain 





















Glycogen ....... Glucose-6-phosphate 






Lactate ....... Pyruvate 

Mitochondrion 








Figure 1. Fuel substrate utilization by the normal heart. Glucose transporter (GLUT), 
hexokinase (HK), phosphofructokinase (PFK), pyruvate dehydrogenase (pDH), acetyl coenzyme A 











3.2.2. Fatty acid metabolism 
FAs have multiple functions, including its role as a primary energy source for the 
adult mammalian heart. 25 Moreover, FAs can also act as mediators of signal 
transduction. For example, pervious studies have shown that FAs may activate 
protein kinase C (PKC), leading to the initiation of the apoptotic cascade. 32 
Furthermore, increased dietary FA intake not only augments the availability of F As 
as a fuel substrate, but can also activate FA metabolic genes by acting as ligands for 
nuclear transcription factors such as peroxisome proliferator-activated receptor alpha 
(PPARa). 33 
FAs are stored as triglycerides (TO) in adipose tissue and released into circulation by 
lipolysis. 29 Free FAs (FFA) are taken up from the bloodstream via several 
sarcolemmal FA transporters, including fatty acid binding protein (F ABP) and fatty 
acid transporter (FAT). 15 Upon uptake into cardiomyocytes, FFAs are activated by 
acyl coenzyme A (acyl-CoA) synthase to form FA acyl-CoAs that are imported into 
the mitochondrion via the carnitine palmitoyltransferase (CPT) shuttle (Fig. 1). 34 
Here, carnitine palm toyltransferase-l (CPTl), located on the outer mitochondrial 
membrane, is the rate-limiting step of mitochondrial FA uptake. After uptake into the 
mitochondria, FA acyl-CoAs subsequently undergo ~-oxidation generating reducing 
equivalents (NADH, FADH2). 
NADH and FADH2, common products arising from glucose and fatty acid metabolic 
pathways, will subsequently enter the mitochondrial respiratory chain, the final 
common pathway in mitochondrial oxidative phosphorylation. Here, oxidation of 
reducing equivalents generates an electrochemical proton gradient (.1IlH) across the 












via ATP synthase, this potential energy is used to generate ATP. It is estimated that 
more that 90% of mitochondrial ATP is generated at this step. 29,35 


































Figure 2. Mitochondrial oxidative phosphorylation. Diagram oj a mitochondrion 
represents the outer (thin line) and inner (thick line) mitochondrial membranes. Superoxide is 
produced by coenzyme Q (CoQ) embedded within the inner mitochondrial membrane. Electron donors 
from the citrate acid cycle (NADH and FADHJJ generate an electrochemical proton gradient (41Ft) 
across the inner mitochondrial membrane. 41Ft decreases as protons re-enter the matrix, generating 
ATP via ATP synthase. Mitochondrial complex 1- NADH-Ubiquinol Oxidoreductase (I), complex ff -
Succinate-Ubiquinol Oxidoreductase (If), complex fff - Ubiquinol-Cytochrome c Oxidoreductase (Iff), 











3.2.3. Insulin and leptin: pivotal regulators of fuel substrate 
utilization 
Intracellular glucose and FA levels are tightly regulated by circulating insulin. 25 
The main function of insulin is to lower elevated postprandial blood glucose levels. 
25, 30, 36 Two major mechanisms for insulin-mediated glucose uptake have thus far 
been identified (Fig. 3): 
1) Insulin promotes glucose uptake and increases both the expressIOn and 
translocation of glucose transporters (e.g. GLUT 4) to the sarcolemma, thereby 
promoting glucose metabolism. 37 Insulin is thought to promote these effects by 
binding to its receptors and initiating a tyrosine kinase cascade via activated protein 
kinases. Increased tyrosine phosphorylation activates insulin receptor substrate-l 
(IRS-I), subsequently leading to an activation of hosphatidylinostitol-3 kinase (PI3 
Kinase) and protein kinase B (PKB, also known as Akt). Akt/ PKB activation results 
in translocation of insulin and GLUT 4 from intracellular vesicles to the sarcolemma, 
thereby increasing capacity for glucose uptake. Activation of Akt/ PKB also 
stimulates pro-survival pathways which inhibit apoptosis, the programmed cell-death 
pathway. 25 
2) Insulin suppresses the secretion of FFAs from adipose tissue, thereby reducing 
FF A supply, metabolism and its inhibitory effects on glycolysis. Here it is proposed 
that elevated FF A supply and subsequent FA oxidation result in increased 
acetyl-CoAl CoA and NADHI NAD+ production. These by-products of FA oxidation 
are thought to activate PDH kinase, an inhibitor of PDH. This in turn will result in 
reduced glucose oxidation. 38 Thus, inhibition of FA oxidation should reduce the 



















i Glucose uptake Apoptosis 
Figure 3. Action of insulin. Insulin, via its receptor, stimulates glucose uptake by increasing 
the translocation ofinsulin and glucose transporter-4 (GLUT 4) to the sarcolemma. It also stimulates 
pro-survival pathways (inhibit apoptosis and promote growth) regulated by PI3 Kinase and Akt! PKB. 
Insulin receptor substrate -1 (IRS-I), tyrosine phosphorylation (Tyr-P) , phosphatidylinostitol-3 kinase 
(pI3 Kinase), protein kinase B (pKB, also known as Akt), glucose transporter-4 (GLUT 4). 
Leptin, another important liporegulatory hormone, is thought to act in concert with 
insulin. 39, 40 It is secreted by adipose tissue and acts via Janus kinasel signal 
transducers and activator of transcription (JAKf STAT) pathways. Leptin is known to 
regulate energy balance by decreasing food intake, increasing energy expenditure 
and stimulating adipose proliferation via the hypothalamus. 41-43 It regulates many 
well-known insulin downstream targets such as IRS-I, PI3 kinase, AktI PKB and 
mitogen-activated protein (MAP) kinase. 
Since its discovery in 1994, 44 many studies have shown that leptin stimulates cardiac 











from adipose tissue, b) increasing FA oxidation capacity in peripheral tissues and c) 
reducing lipogenic capability. 43,45 If such liporegulatory effects are impaired for e.g. 
due to leptin deficiency or leptin resistance, this will result in hyperphagia 43 In 
agreement with this, studies have also found that hyperleptinemia is often associated 
with diet-induced obesity and subjects display reduced responsiveness to leptin 
treatment. 46, 47 Leptin deficiency (low leptin levels) or resistance results in 
hyperplasia and obesity which has been suggested to playa role in the development 
of metabolic syndrome i.e. it lowers insulin secretion and is associated with 
hyperinsulinemia 48 
3.3. Type II diabetes: altered metabolic signatures 
The causes of metabolic syndrome and type II diabetes are attributed to central 
obesity as a consequence of excess nutrient intake, sedentary lifestyle and 
genetics. 13, 49 However, these causes share a common factor i.e. the inability of 
insulin to adequately respond to increases in systemic glucose and FFA levels. 
Resulting lipid! lipoprotein abnormalities and impaired glucose metabolism, 
ultimately leads to major metabolic consequences such as hyperglycemia and 
dyslipidemia. 13,38 
Insulin resistance is the basis of the pathophysiology of metabolic syndrome and type 
II diabetes. 13, 38 Himsworth 50 was the first to suggest that patients with diabetes 
should be divided into "insulin sensitive" and "insulin insensitive" categories and 
argued that "all causes of human diabetes could be explained by deficiency of 













3.3.1. FFAs and reduced insulin sensitivity 
Reduction of insulin sensitivity has been attributed to the abundant supply of 
circulating FF As. 13 FF As are released mainly from TGs stored in adipose tissue. 
Here, lipoprotein lipase releases FF As into circulation through lipolysis. 51 Insulin 
has profound modulatory effects on systemic FF A levels i.e. it inhibits lipolysis 
thereby reducing FF A release. 52 
In healthy individuals, increased insulin infusion resulted in reduced systemic FF A 
while glucose levels remained constant. 53 However, in patients with metabolic 
syndrome and diabetes, insulin appears to be less efficient! sensitive in suppressing 
systemic FF A releasing from adipose tissue and regulating its metabolism. 15 In 
contrast to the normal physiologic context, insulin increases rather than inhibits 
lipolysis in this instance. 54 As a result, circulating FF A levels are further increased. 
Although FF As have the ability to stimulate insulin secretion, prolonged exposure to 
excessively high FF A levels is thought to reduce insulin secretion through increased 
~-cell apoptosis. 13,55,56 
Excessive circulating FF A levels have been suggested to not only contribute to 
insulin resistance, but have also been implicated in reduced glucose uptake in 
peripheral tissues like skeletal muscle and heart. 13,38,57 
3.3.2. FFAs and impaired glucose transport! oxidation 
Patients with elevated FF A supply display impaired insulin action on glucose 
metabolism. 58, 59 This includes increased hepatic gluconeogenesis and attenuated 
insulin-mediated glucose transport and oxidation. 27, 36, 60 Potential FF A-mediated 











FF As reduce insulin sensitivity and inhibit insulin-mediated glucose uptake in 
skeletal muscle. 59 This is the consequence of FF A-induced inhibitory effects on 
insulin-mediated glucose transport. 58,61 Here, the concept proposed is that increased 
FA uptake exceeds oxidation capacity leading to the accumulation of intracellular FA 
metabolites such as acyl-CoAs, diacylglycerol (DAG) and ceramides. It has been 
suggested that these metabolites activate PKC and a downstream serine/ threonine 
kinase cascade. 32, 59, 62 This in turn leads to increased serine phosphorylation of 
IRS- I, thereby blocking IRS-l tyrosine phosphorylation and inhibiting the activity of 
PI3 kinase and Aktl PKB, major stimulators of GLUT 4 translocation. lbis inhibition 
results in impaired insulin-mediated glucose transport. Moreover, inhibition of the 
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Figure 4. Potential mechanisms of FA-induced impairment of insulin-mediated 
glucose transport. With type II diabetes, prolonged exposure to excessive FFA levels increase 
intracellular FA acyl-CoA, DAG and ceramide content which may lead to an impairment of insulin 
Signaling and inhibition ofinsulin-mediated glucose transport. Excess intracellular FA acyl-CoA may 
also promote apoptosis via inhibition ofAktlPKB and ceramide-induced lipoapoptosis. Acyl coenzyme 
A (acyl-CoA), diacylglycerol (DAG), insulin receptor substrate -1 (IRS-I), serine phosphorylation 
(Ser-P), tyrosine phosphorylation (Tyr-P), phosphatidylinostitol-3 kinase (p13 Kinase), protein kinase 
B (PKB, also known as Akt), glucose transporter (GLUT 4). 
Based on Randle's theory, 38 increased FA oxidation will result in the inhibition of 
glucose oxidation. Elevated FA oxidation increases the production of acetyl-CoAl 
CoA and NADHI NAD+ which activates PDH kinase, an inhibitor of PDH. Reduced 











metabolites e.g. fructose-6-phosphate and pyruvate. 34 Previous studies reported that 
the rate of glycolysis was reduced in isolated perfused diabetic hearts and in normal 
hearts perfused with fatty acids and ketones. 38, 49, 63 The authors suggested that 
elevated systemic FF A levels leads to an increase in glycogen content, which may 
contribute to the reduced rates of glycolysis observed with diabetes. 38,49,63 Thus, 
glycolysis and glucose oxidation are downreguiated in the diabetic heart (Fig. 5). 
13,36, 64 Moreover, it has been shown that dichloroacetate, a PDH kinase inhibitor, 
increases pyruvate oxidation and myocardial contractility in diabetic and to a lesser 
extent in healthy subjects. 57 These results provide additional support for the concept 
that attenuated PDH activity plays an important role in impaired contractile function 
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Figure 5. Inhibition of pyruvate oxidation during diabetes. Increased FFA supply and 
uptake leads to elevated rates of FA oxidation. As a result, increased acetyl-CoAl CoA and NADHI 
NAD+ stimulate the acitivity ofpyruvate dehydrogenase (PDH) kinase which in turn inactivates PDH, 
causing the inhibition ofglucose oxidation. Increased citrate levels will also downregulate PFK, the 












3.3.3. FF As and hyperinsulinemia/ hyperglycemia 
A previous study has reported that not only insulin resistant diabetic patients but 
also - 25% of non-obese insulin resistant patients developed impaired glucose 
tolerance. 65 Hollenbeck et al. (1987) 66 and Golay et al. (1986) 65 have suggested 
that it is normal for patients with insulin resistance to develop glucose tolerance as a 
compensatory effect. They argued that when these patients produce sufficient insulin 
to compensate for the insulin resistance to maintain euglycemic state, it reflects the 
ability of ~-cells to regulate insulin secretion. However, if ~-cells cannot sustain the 
hyperinsulinemic state, it will lead to a gross decompensation of glucose homeostasis. 
66,17 Together with the FFA-induced hepatic gluconeogenesis and the impairment of 
insulin-stimulated glucose transport and oxidation, severe hyperglycemia will 
develop (Fig. 6). 27,36,60 
Moreover, increased circulating insulin stimulates a) release of pro-inflammatory 
cytokines such as interleukin 6 (IL-6), tumour necrosis factor a (TNFa) and 
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Figure 6. Development of hyperinsulinemia and hyperglycemia due to excess 
FFA. 












3.3.4. FFAs and dyslipidemia 
With diabetes, due to the inability of insulin to respond to the increase in systemic 
circulating FF A levels, lipoprotein abnormities occur. Here, increased FF A flux to 
the liver stimulate an overproduction of hepatic TO and TO-rich very low density 
lipoproteins (VLDL) into the circulation. 67 It also suppresses the production of the 
beneficial high-density lipoproteins (HDL) and lipoprotein lipase leading to 
inhibitory effects on lipoprotein degradation. I3 
Diabetic hearts with insulin resistance are continuously exposed to a hyperlipidemic 
and hyperglycemic environment. 26 It initially adapts to this condition by increasing 
the gene expression of various proteins involved in FA oxidation and utilization 
e.g. PPARa and its target genes like CPTI and uncoupling protein 3 (UCP3). 68,69 
However, as soon as sarcolemmal FA uptake exceeds its oxidative capacity, F As 
begin to accumulate in organs like liver, pancreatic islet, skeletal muscle, cardiac 
muscle, etc. This phenomenon of lipid deposition is often referred to as 
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Figure 7. Lipotoxicity. Lipotoxicity is a consequence of lipid overload which results in 
intracellular FA accumulation in organs like liver and cardiac muscle. Subsequently, central and 
peripheral leptin resistance and lipid-induced programmed cell death "/ipoapoptosis" through de 
novo ceramide lipotoxicity may occur. Prolonged exposure to this harmful environment will eventually 
lead to contractile dysfunction of the heart. Triglyceride (TG), very low-density lipoprotein (VLDL) 











Lipid accumulation (lipotoxicity) in the liver i.e. non-alcoholic steatohepatitis 
(NASH) has been described clinically. 70, 71 Lipotoxicity includes lipid-induced 
programmed cell death i.e. "lipoapoptosis". Here, de novo ceramide formation and 
excessive ROS production have been implicated as prime mediators of this condition. 
72-74 Prolonged exposure of the heart to this metabolic environment may contribute to 
the reduction of cardiac contractile function. 26,27, 75, 76 For example, in the clinical 
setting this pathological abnormality may result in lipotoxic cardiomyopathy. 49, 63 
3.3.5. Perturbation of mitochondrial energy production 
Recently, it has been reported that increased FA oxidation flux associated with the 
diabetic phenotype results in downregulation of nuclear-encoded genes necessary for 
mitochondrial oxidative phosphorylation. 69 Also, pivotal transcriptional modulators 
regulating mitochondrial biogenesis were reported to be downregulated with 
diabetes. 77 Moreover, increased FA oxidation flux induces mitochondrial superoxide 
production from co-enzyme Q (CoQ) of the electron transport chain. 35 FA-induced 
superoxide is associated with increased mitochondrial uncoupling in obese hearts. 35, 
78 Such metabolic perturbations are thought to mediate mitochondrial dysfunction, 
thereby contributing to the development of contractile dysfunction of the diabetic 
heart. 79 
Elevated systemic FF A levels have been associated with increased expression of 
uncoupling proteins (VCPs), located within the inner mitochondrial membrane. 69, 
80-82 Two isofonns i.e. uncoupling protein 2 (VCP2) and uncoupling protein 3 (VCP3) 
are expressed in the heart. UCP2 is ubiquitously expressed whereas UCP3 is 
enriched mainly in skeletal muscle and heart. 79-81 The precise functional roles of 












uncouple mitochondrial oxidative phosphorylation by translocation of protons from 
the inter-mitochondrial membrane space into the matrix. 83 Conversely, other 
functional roles for cardiac-enriched UCPs include the regulation of lipid oxidation, 
efficiency in energy production of the heart, and acting as an antioxidant 
defense system to prevent lipid-induced oxidative damage in the heart. 80, 81,84,85 For 
example, a starvation and refeeding study demonstrated a positive correlation 
between FF A concentration and UCP3 gene expression, suggesting that UCP3 may 
be involved in the regulation of FA oxidation. 79, 86 On the other hand, UCP2 is 
thought to form part of the antioxidant defense mechanism in the heart, acting to 
prevent damaging ROS production. 84, 85,87,88 Additional studies are required to fully 
delineate the precise roles of UCPs in the heart. 
Elevated FA utilization is a hallmark of the obese and diabetic heart. 27, 82, 89 
Recently, a study done by Carley et al. (2005) 27 has shown reduced cardiac 
efficiency (work! myocardial oxygen consumption) in the working rat heart when 
perfused with high FA levels and myocardial oxygen consumption (MV02) was 
unchanged. However, Boudina et al. (2005) 82 reported increased MV02 and 
reduced cardiac efficiency in ob/ob mice, a transgenic mouse model of 
obesity-induced type II diabetes. Moreover, they found attenuated mitochondrial 
respiratory function in these mice. Differences in MV02 may be due to variation in 
animal models and/or experimental protocols employed. However, the latter study 
suggests that cardiac mitochondrial oxidation capacity is reduced in diabetic mice. 
This suggested ''wastage'' of oxygen and possibly due to uncoupling of 
mitochondrial ATP production and oxygen consumption. The precise mechanisms for 
this reduction are not fully understood, although it has been suggested that elevated 












thereby reducing contractile function (Fig. 8). 
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Figure 8. Mitochondrial dysfunction may result from FA-induced mitochondrial 
uncoupling and increased ROS production. Diagram of a mitochondrion represenls the 
outer (thin line) and inner (thick line) mitochondrial membranes. UCPs may increase proton leak 
across the mitochondrial inner membrane and decrease the electrochemical potenlial, thereby 
reducing the production ofATP. Superoxide generated by coenzyme Q (CoQ), is suggested to promote 
additional proton leak and thereby further reducing mitochondrial ATP production. Mitochondrial 
complex f - NADH-Ubiquinol Oxidoreductase (f) , complex II - Succinate-Ubiquinol Oxidoreductase 












Interestingly, a recent study has shown that males produce approximately twice the 
amount of mitochondrial hydrogen peroxide (H20 2) compared to females. 90 Here, 
higher HDL cholesterol levels and antioxidant gene expression for e.g. glutathione 
and manganese-superoxide dismutase (Mn-SOD) have been suggested to contribute 
to diminished oxidative damage in females. 90, 91 , 92, 93 An interesting question 
therefore arises i.e. what activates/ causes such gender-protective mechanisms? It is 
possible that such differences may be attributed (in part) to hormonal profiles. In 
agreement, a recent study showed that estrogen exerts an antioxidant effect by 
upregulating antioxidant gene expression via MAP kinase sig aling and nuclear 












With obesity-induced insulin resistance! type II diabetes, excessive FFA supply 
decreases mitochondrial bioenergetic capacity. Moreover, we propose that females 
possess innate cardioprotective programs that will result in enhanced bioenergetic 
capacity compared to males (Fig. 9). 
To investigate our hypothesis, we measured cardiac mitochondrial respiratory 
function and histological parameters in two rodent models of obesity i.e. a) a diet 
induced-obesity rat model and b) an obesity-induced type II leptin receptor deficient 
diabetic mouse model (db/db): 
1. 	 Mitochondrial respiratory functional analysis in cafeteria diet-induced obese 
Wistar rats. 
2. 	 Age-dependent mitochondrial respiratory function in male db/+ and db/db mice 
aged 10-12 weeks and 18-20 weeks, respectively. 
3. 	 Gender-dependent mitochondrial respiratory function by comparing male and 
female db/+ and db/db mice at age 18-20 weeks. 
4. 	 Pilot study of mitochondrial respiratory function by comparing male and female 
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Figure 9. Schematic of proposed hypothesis. Elevated FFA supply to the insulin 
resistant/diabetic heart increases mitochondrial uncoupling via cardiac-enriched uncoupling proteins, 
thereby reducing mitochondrial energy production. Mitochondrial complex / - NADH-Ubiquinol 
Oxidoreductase (/); complex II - Succinate-Ubiquinol Oxidoreductase (I/) ; complex II/ ­
Ubiquinol-Cytochrome c Oxidoreductase (II/); complex IV - Cytochrome c Oxidase (IV); coenzyme Q 























5. Material and Methods 
5.1. Choice of rodent models of obesity and type II 
diabetes for this study 
Most studies investigating mitochondrial respiration in diabetes were performed 
using streptozotocin (STZ)-induced type I diabetic animal models. Since 
21 stobesity-related type II diabetes is a "growing epidemic" in the century, 
genetically modified rodent models have been developed to more closely simulate 
the phenotype of type II diabetes e.g. db/db, ob/ob and Zucker fatty rats (ZDF) 
models. 27 These animal models exhibit the phenotype of obesity, insulin resistance, 
hyperglycemia and dyslipidemia (Table 7). 
Table 7. Phenotypic characterization of rodent models with type n diabetes 
Model Obesity Plasma 
glucose 
Plasma FA Plasma 
TG 
Mutations in Jeptin 
receptor: 
• db/db mouse 
• ZDFrat 
Mutations in Jeptin: 















Data obtained and modified from Carley et al. (2005) 11 
The db/db mouse is an inbred strain with a point mutation in the leptin receptor gene, 
(Lepr). 27 Plasma insulin levels increase as early as day lOin db/db mice, with fJ-cell 
hypertrophy. 76 As body weight increases (3-4 weeks), insulin resistance begins to set 











metabolic syndrome i.e. plasma glucose, insulin, plasma TO and FA levels are 
elevated associated with a reduction in cardiac power and output. 76, 94, 95 By 8-12 
weeks, the pancreatic ~-cells hypertrophies and plasma insulin content reaches the 
peak: which will then drop back to normal levels. 94,96 However, heterozygous mice 
(db/+) are phenotypically normal. 
Notably, the metabolic profile of type II diabetes in db/db mice is similar to the 
human condition. Thus it makes the db/db strain an ideal rodent model for obesity, 
metabolic syndrome and type II diabetes research. 
For the purpose of the present study, we employed two rodent models of obesity to 
investigate our hypothesis i.e. a) a diet-induced obese rat model and b) genetically 
modified mouse model (db/db) to imitate the progression from obesity-induced 
insulin resistant state (diet-induced obese rat model) to a type II diabetes state (db/db 
mouse model). 
5.2. Diet-i duced obese rat model (cafeteria diet feeding) 
This section of the study forms part of a collaborative project with Dr. Eugene du 
Toit of the Department of Medical Physiology at the University of Stellenbosch. 
Six-week-old male Wistar rats (200 g) were housed under conditions of constant 
temperature and humidity and exposed to a 12 hour light-12 hour dark cycle with 
access to food and water ad libitum. Rats were randomly assigned in two groups: 
control and obese. Rats from the control group were fed with normal chow 
comprised of 60% carbohydrate, 30% protein and 10% fat. Rats within the obese 
















carbohydrate, 19% protein and 16% fat (refer Appendix). Animals were anesthetized 
using a combination of sodium pentobarbital (100 mg/kg intra-peritoneally) and 
heparin (50 International Units, Centaur Labs). Fasting plasma insulin, HbAlc test 
(glycosylated hemoglobin Alc test), non-esterified fatty acid (NEFA), TG and HDL 
cholesterol levels were measured by members of Dr. du Toil's laboratory. Unlike 
daily blood glucose testing, no fasting is required for the HbAlc test. It is regarded as 
a more precise measurement of hyperglycemia. The test measures the level of 
glycosylated hemoglobin. It provides a clearer profile of glucose levels of over the 
course of several months. 
5.2.1. Mitochondrial isolation 
Mitochondria were isolated using the method of Sordahl et al. (1971) 97 with 
modifications. Ventricular tissues (the whole heart) were minced and rinsed 
thoroughly to prevent blood contamination which affects the quality of isolated 
mitochondria and consequently reduces the rate of mitochondrial respiration. 
Thereafter, the tissue was gently homogenized in 3 ml ice-cold potassium-EDT A (KE) 
isolation buffer (Appendix) using a glass homogenizer (Tenbroek, Netherlands) and 
the homogenate was centrifuged at 755g (Beckman J2-21M, USA) for 5 minutes at 4 
°C to eliminate the cellular debris. The supernatant was subsequently centrifuged at 
1,480g for 5 minutes and the mitochondrial pellet resuspended gently in 100 III of 
incubation buffer (Appendix) and kept on ice at all times. Mitochondrial protein 
concentrations were determined using the method of Lowry et al. (1951). 98 
5.2.2. Protein quantitation 
Five fll ofmitochondrial protein was added into 1 ml of distilled water (performed in 

















for 10 minutes at room temperature followed by the addition of 0.5 ml solution B 
(Appendix) for 30 minutes to allow for the development of full color. Due to the 
short half-life of the latter reagent, the mixture was vortexed immediately upon 
addition of solution B. A standard curve was constructed using 2 ).1g/J.11 of bovine 
serum albumin fraction V (BSA) (Sigma, Germany) and was prepared as detailed in 
Table 8. The sample is read in a spectrophotometer (Varian 130 dual beam) at 750 
nm wavelength and the concentration of the sample protein was expressed as 
microgram ofmitochondrial protein per 5 J.1l. 
Table 8. Construction ofstandard curve for protein quantitation 
BSA quantity Distilled water added 
Amount of 2).1g/J.11 BSA 
added 
0 1000 ).11 0 
5 J.1g 997.5 ).11 2.5 ).11 
10 ).1g 995 J.11 5 ).11 
20 J.1g 990 J.11 10 J.1l 
50 J.1g 975 J.11 25 J.11 
100 J.1g 950 J.11 50 J.11 
150 J.1g 925 J.11 75 ).11 
200 ).1g 900 ).11 100 ).11 
5..2..3.. Standard mitochondrial oxygen consumption parameters 
Mitochondrial respiratory function was polarographically measured at 25°C using a 
thermostatically controlled Clark-type electrode. and a rapid stirring device 
(Hansatech Instruments, London, UK). Incubation buffer (Appendix) was used to 
calibrate the respirometer and a baseline reading was recorded (for 1 minute) to 
verify the calibration. Experiments were performed using glycolytic (glutamate) and 











Respiratory parameters were determined as described previously. 88 
To initiate experiments, 50 !J.I of heart mitochondria was added (after 1 minute 

equilibration) to the electrode chamber containing 340 !!1 incubation buffer. 

Mitochondrial respiration was initiated by the addition of substrate for e.g. 12.5 mM 

glutamate. State 3 respiration was stimulated by the addition of ADP to a final 

concentration of 714 !J.M. Mitochondrial respiration was also measured using fatty 

acid substrates (3.3 mM of malate and 54 !J.M of CP).Total volume of the reaction 

was 819 !J.l. 

Standard respiratory parameters measured include: 









State 3 respiration - mitochondrial oxygen consumption stimulated by ADP, where 

oxygen is used to phosphorylate ADP to ATP. 

State 4 respiration - mitochondrial oxygen consumption after completion of ADP 

phosphorylation. It is a marker for endogenous uncoupling. 

ADP/O ratio - ratio between nmol of ADP phosphorylated and oxygen consumed (in 

atoms) during state 3 respiration. It is an indicator for the ability of mitochondria to 

link oxygen used for the phosphorylation ofADP. [Babsky; 2001] 

Rate ofphosphorylation - nmol of ADP phosphorylated per minute during state 3 






















5.2.4. Percentage recovery of state 3 respiration after anoxia 
The ability of mitochondria to recover respiratory capacity after an anoxic stress was 
also determined. Here, anoxia was achieved by addition of ADP to a fmal 
concentration of 7.14 mM after state 4 respiration was reached (Fig. 10). The 
underlying principle being that a 10 times more concentrated ADP concentration 
added to the closed chamber will result in all remaining oxygen in the chamber being 
used to convert ADP to ATP until an anaerobic condition has been reached. The 
chamber was sealed for 20 minutes after ADP addition. The chamber was thereafter 
opened for 1 minute of reoxygenation (open chamber and bubble through using 
disposable plastic pipette). Thereafter, the oxygraph chamber was closed again and 
state 3 respiration determined for the remaining substrate. The rate of recovery of 
state 3 respiration after 15 minutes of anoxia was determined by measuring the 
oxygen uptake for 5 minutes and the percentage of recovery after 20 minutes of 
anoxia was calculated as per the following equation: 
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Figure 10. Experimental protocol of mitochondrial respiration in response to an 
anoxic stress. A typical polarographic trace ofoxygen consumption during anoxia-reoxygenation. 
State 2 respiration was stimulated by 3.3 mM malate and 54 pM carnitine-L-palmitoy/. State 3 
respiration was stimulated by the addition of 714 pM ADP Anoxia was achieved by addition of 714 
pM of 100 mM ADP after state 4 respiration was reached. Mitochondria (Milo), malate (M) and 
carnitine-L-palmitoyl (ep). 
5.3. Transgenic mouse model of type II diabetes 
Leptin receptor deficient db/db mice (aged 10-12, 18-20 and 55-56 weeks) were 
housed under conditions of constant temperature and humidity and exposed to a 12 
hour light-12 hour dark cycle. Free access to standard mouse chow and water were 











Le. the age-matched heterozygous control db/+ and homozygous mutant db/db mice. 
Based on previous studies from our collaborators in Norway, age-dependent changes 
in cardiac metabolism were detected i.e. at ages 10-12 weeks and 16-18 weeks. 7S For 
this study we employed two time points i.e. 10-12 and 18-20 weeks. We also did a 
pilot study at a later time point i.e. 55-56 weeks. Animals were anesthetized using 
sodium pentobarbital (50mg/kg intra-peritoneally, Centaur Labs) and heparinized to 
prevent blood clotting (50 International Units, UNIPRINT-L). Subsequently, mouse 
hearts were dissected out for mitochondrial isolation. All animals used in this study 
were the BKB.Cg-m+/+Leprdb/J strain, obtained from the Animal Unit of University 
of Cape Town's Faculty of Health Sciences and The Jackson Laboratories (Bar 
Harbor, Maine): Experiments were approved by University of Cape Townts Animal 
Research Ethics Committee and the investigation conforms to the Guide for the Care 
and Use of Laboratory Animals published by the US National Institutes of Health 
(NIH Publication No. 85-23, revised 1996). 
Stavinoha et al. (2004) 99 demonstrated a diurnal variation in cardiac fatty acid 
metabolism, with greatest responsiveness being displayed during the dark cycle. In 
light of this, we employed a reverse dark cycle to ensure that our experimental work 
was performed during the middle of the dark cycle. Three weeks before mice were to 
be sacrificed they were housed in a separate animal room. The strict 12 hour light-12 
hour dark cycle regime was enforced (lights switched on at 4:00 pm and switched off 
at 4:00 am and termed zeitgeber time [Zl1 0 and 24, respectively). Two weeks 
before mice were sacrificed, fasting blood glucose levels were measured using a 
glucose-meter (ACCU-CHEK® Active Meter, Roche) after a 6 hours fast. For the 


















(UriCHECK 9, South Africa). After 3 weeks of acclimatization, mIce were 
euthanized at ZT 17 - 19. 
Note: Heparin is known to stimulate the activity of lipoprotein lipase. It acts upon 
TG associated with blood lipoproteins, resulting in release of FF As. Hence, heparin 
is not suitable for blood collection and determination ofplasma FFAlevels. 100 
5.3.1. Mitochondrial isolation 
Mitochondria were isolated using the method ofSordahl et al. (1971) 97 as described 
in section 5.2.1. with modifications. After homogenization, the homogenate was 
centrifuged at 660g (Sigma 202MK, Germany) for 5 minutes at 4 °C to eliminate the 
cellular debris. The supernatant was subsequently centrifuged at 960g for 5 minutes 
and the mitochondrial pellet resuspended gently in 50 ~l of incubation buffer 
(Appendix) and kept on ice at all times. Mitochondrial protein concentrations were 
determined using the method ofLowry et al. (1951) as described in section 5.2.2. 98 
5.3.2. Standard mitochondrial oxygen consumption parameters 
Mitochondrial respiratory function was polarographically measured at 25°C using a 
thermostatically controlled Oxytherm equipped with Clark-type electrode and a rapid 
stirring device (Hansatech Instruments, London, UK). Incubation buffer (Appendix) 
was incubated in the Oxytherm for approximately one minute before the start of each 
experiment, during which time a baseline reading was recorded and used to verify 
the calibration. Experiments were performed using fatty acid (MCP) as substrate. 
After one minute of equilibration period, 25 J.11 of heart mitochondria was added to 
the electrode chamber containing incubation buffer to a final volume of 420 J.1l. 
Mitochondrial respiration was initiated by the addition of substrates for e.g. 7 mM 
41 
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malate and 25 ~M CPo State 3 respiration was stimulated by the addition of 300 ~ 
ofADP. 
5.3.3. Percentage recovery ofstate 3 respiration after anoxia 
Similar to diet-fed rats, anoxia was achieved by the addition ofan additional 300 ~ 
of ADP after state 4 respiration was reached. A 10 times more concentrated ADP 
solution was added to the closed chamber to facilitate maximal mitochondrial 
respiration. As a result, oxygen in the closed chamber was all used to convert ADP to 
ATP and an anaerobic condition was reached. The chamber was sealed for 20 
minutes followed by I minute of reoxygenation (open chamber and bubble 
throughout using a disposable plastic pipette). Thereafter, the oxygraph chamber was 
closed again and the remaining substrates were used for mitochondrial respiration. 
The rate of recovery after 20 minutes anoxia was estimated by measuring 5 minutes 
of the oxygen uptake. The percentage of recovery after anoxia was calculated the 
same way as for the diet fed rats: 
% Recovery of state 3 respiration (State 3a I State 3) x 100. 
5.3.4. Determination of plasma glucose levels 
Blood was collected by cardiac puncture at both experimental time points to 
determine the plasma glucose levels. Body weights were measured after the animals 
were anesthetized using a combination of ketamine and xylosine (50mg/kg 
intra-peritoneally). Blood was collected and left at room temperature for one hour 
before centrifugation (Sigma 202 MK) at 660g for 5 minutes to obtain maximum 

















Department of·Chemical Pathology (Groote Schuur Hospital, South Africa) to 
determine plasma glucose levels. It was measured using a spectrophotometric 
glucose oxidase method. 101 
5.3.5. Measurement of mitochondrial ATP 
Mitochondrial ATP concentration was assayed using a luciferin-Iuciferase 
luminometry luminescence method modified from Fryer et al. (2000) 102, Freshly 
isolated mitochondria were placed into boiling water (3 x sample volume) for 10 
minutes and thereafter on ice for 10 minutes to disrupt mitochondrial membranes. 
The mixture was subsequently centrifuged at 960g for 5 minutes (Sigma 202MK, 
Germany) at 4°C. A 10 ",I of supernatant was added into 175 III of distilled water 
and 25 ",I firefly (Bioluminescent Somatic Cell Assay Kit (FL-AA), Sigma Germany). 
The principle being that firefly contains luciferin and luciferase, commonly used in 
medical research laboratories worldwide, two rare chemicals which are not able to be 
produced synthetically. The reaction of luciferin-luciferase mixture, energy donor 
(ATP) and oxygen results in the emission of light. The intensity of the 
bioluminescence detected from the luminometer was used to be determined the 
concentration of mitochondrial ATP within the mitochondria. Mitochondrial protein 
concentration was determined using the Lowry assay 98, and the standard curve was 
constructed using 1 x 10-5 M to 1 x 10.9 M of ATP. The concentration of 
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5.3.6. Histology and electron microscopy 
After the mouse hearts were weighed to detennine the heart to body weight ratio, the 
remaining heart tissues were collected for histological analysis. A total of six cross 
sections of heart tissues were collected for histology and three small portions of the 
left ventricle were collected for electron microscopy (EM). Small portions of heart 
tissues generated from cardiac puncture were stored in 10% formaldehyde (formalin) 
for hematoxylin and eosin (H&E) staining and glutaraldehyde for osmiwn tetroxide 
(OS04) staining or EM. All tissue specimens were stored in fixative and sent to the 
Department of Anatomical Pathology, University of Cape Town for further 
preparation (Appendix). Electron microscopic analysis was performed at the Electron 
Microscopy Uni~ University of Cape Town. Five representative blocks on the grid 
were selected and the whole area was examined under high magnification 25 OOOX. 
Pictures were taken ofrepresentative mitochondria. 
Tissue specimens are generally prepared via the following steps: 103 
Fixation - To stabilize and preserve fresh tissue morphology and molecular 
composition. Routine fixation such as formaldehyde (formalin) and glutaraldehyde 
are used to stabilize molecular structure to minimize shrinkage and swelling. The 
advantage of formaldehyde is the higher rate of tissue penetration compared to 
glutaraldehyde or OS04. Thus, this procedure allows for large blocks of tissue to be 
fixed. However, formaldehyde is not the ideal fixative for EM, yielding poorer image 
quality compared to OS04. 
Embedding - To provide support to sectioning. A thin tissue section can be sliced by 
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Sectioning! slicing - To provide very thin specimen for microscopy. A typical 
thickness for light microscopy is 4-6 !lm and 50-100 nm for EM. 
Staining - To provide a visual contrast in the transparent tissue sections and help 
distinguish intracellular compartmentation and dilforent ultrastructural components. 
For light microscopy studies, colored stains (termed chromophores) such as H&E 
staining are widely used. However, for EM studies, electron-dense heavy metal salts 
such as lead citrate and uranyl acetate are employed. Most of the colored stains 
bind selectively to particular components due to their chemical behavior. The basic 
stain with an affinity for negatively charged nuclei and ribosomes are termed 
basophilic. The acid stain with an affinity for positively charged cytoplasm and 
mitochondria are termed acidophilic. 
i) Hematoxylin and eosin staining 
The combination of hematoxylin and eosin is the most widely used general purpose 
stains i.e. useful in visualizing the various tissue components and differentiating one 
cell component from another. Hematoxylin is a basic stain with an affinity for 
basophilic cell components like nuclei and ribosomes-stains deep purple or blue color. 
The acidic eosin stains cytoplasm, mitochondria, muscle and connective tissues in 
pink (Appendix). 104 
ii) Osmium tetroxide staining 
OS04 has a strong affinity for lipid. It is not only used as a fixative but as a stain for 
lipids as well. It is one of the oldest stains for visualizing unsaturated fatty acids (it 
reacts primarily with the double carbon bonds ofunsaturated fatty acids such as oleic 
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well documented advantages of 0804 are the preservation of the ultrastructural 
features, strong affinity for lipids and osmium blackening. The reduction of 
unsaturated fatty acids and the alcohol dehydration result in osmium blackening 
(staining) which is responsible for improved visualization and ultrastructural 
preservation (Appendix). 
iii) Electron microscopy 
Electron microscopy functions the same way as nonnal light microscopy except that 
it uses a highly energetic electron beam to provide higher magnification of 
specimens. The two types of electron microscopy include a) two dimensional 
transmission electron microscopy (TEM), and b) three dimensional scanning electron 
microscopy (SEM). In this study we employed TEM to investigate ultrastructural 
abnormalities of mitochondria isolated from diabetic mice. TEM uses the 
transmission of an electron beam that is focused on a metal aperture and magnified 
by a series of condenser lenses. The beam transmits to the specimen and is then 
focused by the objective lens. The objective aperture is used to enhance the contrast 
and the intennediate and the projector lenses magnify the image. These interactions 
are detected and the enlarged image of the specimen is then projected onto the 
monitor or computer system. 105 
5.4. Statistical analysis 
The data is presented as mean ± standard error of the mean (S.E.M.). Statistical 
significance between the groups was perfonned using the unpaired Student's t-test 
using GrapbPad InStat version 3.06 (GrapbPad Software, USA). Values were 
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6. Rat Model of Diet-Induced Obesity 

This part of the study forms part of a collaborative project with Dr. Eugene du'Toit 
(Dept. Medical Physiology, University ofStellenbosch Medical School). 
6.1. Baseline metabolic characterization 
After three months of cafeteria diet feeding, body weight was significantly higher in 
the fed group compared to controls (504.7±12.1 vs. 456.8±16.2 gram [p<O.05]) 
(Table 9). 
Table 9. Metabolic parameters in rats fed cafeteria diet for 3 months 
Control Obese 
Body weight (g) 
Heart: body weight ratios (x 1000) 
Fasting plasma glucose (mmollL) 
Fasting plasma insulin (pIU/ml) 
HbAlc (% Glycosylation) 
FFA(mM) 





















Values are expressed as mean ± S.E.M for 6-13 animals. 
'" p<O. 05 compared with age-matched control rats. 











Also, obese rats displayed significantly increased heart: body weight ratios. 
Moreover, fasting plasma insulin, HbAIc test, NEFA and TO levels were 
significantly elevated and HDL cholesterol level was significantly reduced in the fed 
group versus controls. These parameters (Table 9) were measured by members of Dr. 
du Toit's laboratory. 
6.2. Mitochondrial respiration 
Mitochondria were isolated and respiratory function assessed using standard 
protocols. We also employed different oxidative substrates to gain some insight 
regarding fuel substrate utilization i.e. glycolytic (glutamate) and fatty acid (MCP). 
Endogenous mitochondrial respiration (state 2) was decreased from 22.2±1.0 to 
19.2±0.6 nmoVrninlmg protein (p<O.OS) in mitochondria isolated from obese rats 
when incubated with MCP (Table 10). However, no differences were detected when 
glutamate was employed as substrate. State 3 respiration and ADP/O ratio were 
similar for obese and control mitochondria. ADP phosphorylation rate was decreased 
from 278.I±8.3 to 24S.6±I1.3 nmoVrninlmg protein (p<O.OS) in mitochondria 
isolated from obese rats when incubated with MCP (Fig. 11) Furthermore, state 4 
respiration did not differ when MCP was employed as oxidative substrate. However, 
when glutamate was used as substrate, state 4 respiration was reduced from control 
values of 10.S±1.4 to S.9±l.O nmoVrninlmg protein (p<O.OS) for mitochondria 
isolated from obese mice. 
48 
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Table 10. Standard respiratory parameters for cardiac mitochondria isolated 





Control Obese Control Obese 
State 2 respiration 
(nmollminlmg protein) 
11.2±1.1 lO.8±L2 22.2±l.O 19.2±O.6 * 
State 3 respiration 
(nmollminlmg protein) 
123.4±lS.9 12 LS±8.6 126.2±4.6 117.1±S.O 
State 4 respiration 
(nmollminlmg protein) 
10.S±1.4 S.9±1.0 * 11.8±1.7 14.1±1.8 
ADP/Oratio 2.4±O.1 2.3±O.O3 2.2±O.O6 2.l±O.O4 
Phosphorylation rate 
(nmollminlmg protein) 
298.7±44.6 248.0±22.4 278.1±8.3 24S.6±11.3 * 
Cardiac mitochondria were isolated as described in the Material and Methods section ofthis thesis. 

Respiration parameters were determined at 25°C using glycolytic (glutamate) or fatty acid (malate 
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Figure 11. ADP phosphorylation rate in control vs. obese heart mitochondria. 
MCP was used as substrate. Values are expressed as mean ± S.E.M (n=5-6). 
*p<0.05 compared with age-matched control rats. 
To further assess the effects of diet-induced obesity on mitochondrial respiratory 
function, we exposed mitochondria to a 15 minute anoxic insult followed by 5 
minutes of reoxygenation. We subsequently detennined state 3 respiration (using 
MCP as substrate) as an index of mitochondrial function in response to the anoxic 
stress. Here, the percentage of state 3 recovery was significantly lower in 
mitochondria isolated from obese rats compared to controls (51.7±8.2 vs. 28.7±5.4 
nmoVminlmg protein) (Fig. 12). These data suggest that mitochondria isolated from 

















Figure 12. State 3 respiration recovery in isolated control vs. obese heart 
mitochondria when incubated with MCP. MCP was used as substrate. Values are 











7. 	 Mouse Model of Obesity-induced Type II 
Diabetes 
7.1. 	 Temporal analysis of mitochondrial respiratory 
function 
7.1.1. Baseline metabolic characterization (10-12 weeks) 
For the second part of this study, we investigated mitochondrial respiratory function 
in a leptin receptor-deficient mouse model (db/db) of type 11 diabetes. lbis study 
formed part of a collaborative study with Dr. Ellen Aasum (Department of Medical 
Physiology, University ofTromso, Norway). 
We began our investigations by analyzing metabolic changes in a temporal manner 
i.e. in db/db mice at the age of 10-12 weeks and 18-20 weeks, respectively. Earlier 
studies by our collaborators documented metabolic and functional changes in db/db 
mice aged 10-12 weeks versus control heterozygous littermates db/+. 95, 106 Here, 
they reported that body weight, plasma glucose, free fatty acid and insulin levels 
were significantly increased in db/db mice compared to controls (Table II). 
Moreover, they found reduced contractile function in the db/db mouse compared to 














TabJe 11. Baseline metabolic characteristics of control heterozygous (db/+) and 
obese (db/db) male mice at 10-12 weeks of age 
db/+ db/db 
Body weight (g) 27.9±O.5 43.6±1.2 '" 
• Plasma glucose (mmol/L) # 12.7±O.5 46.2±2.3 '" 
Plasma insulin (pIU/ml) 34±9 '" 
2.I±0.2 '" 

Data adaptedfrom Aasum et oJ. (2003). 75 Values are expressed as mean ± S.E.M 4-16 anima/so 
*p<0.05 compared with age-matched db/+ mice. # Postprandial levels were determined 
this we not set out to re-measure thes  parameters mIce 10-12 
YV\.A.,ft.£>_ However, when we compared 10-12 week old db/db vs. mice, 
acrosc:oDJIC differences were readily aDlJar,ent body mass internal fat content 
were markedly increased for obese db/db compared to matched controls 











Figure 13. Pbotograph of the heterozygous control (db/+) (on the left) and 
homozygous mutant (db/db) (on the right) at age 10-12 weeks. 
Figure 14. Internal fat content of the control mouse (db/+) (on the left) and 
matched homozygous mutant (db/db) (on the right) at age 10-12 weeks. 
7.1.2. Baseline metabolic characterization (18-20 weeks) 
At 18-20 weeks of age, we found that body weight was markedly increased in obese 
mice compared to matched controls (Table 12). Consonant with metabolic data for 
the earlier time point (10-12 weeks), we observed that plasma glucose levels were 
also significantly increased in the db/db mice versus controls. However, the degree of 












point (Note: plasma glucose levels at 10-12 weeks were measured by Dr. Ellen 
Aasum's laboratory and we used a glucose-meter [ACCU-CHECK@ Active Meter, 
Roche] for the 18-20 week point). 
Table 12. Baseline metabolic characterization of heterozygous (db/+) and 
diabetic (db/db) mice at 10-12 and 18-20 weeks of age 
10-12 weeks 18-20 weeks 
db/+ db/db db/+ db/db 
Body weight (g) 





1.2 ± 0.2 
0.5 ± 0.04 
47.0±0.8 * 
32.2±1.6 * 
4.8 ± 0.8 * 









Data at 10-12 weeks was published in How et al. (2006). 106 Values are expressed as mean ± SE.M 
for 6-19 animals. 
N.D = Not determined 
*p <O. 05 compared with age-matched heterozygous db/+ mice. 
§ p<O. 001 compared with age-matched heterozygous db/+ mice. 
7.1.3. Mitochondrial respiration 
After establishing baseline parameters, we next measured respiration In isolated 
mitochondria from db/+ and db/db hearts at the 10-12 week and 18-20 week time 
points. Here, state 2 respiration was similar between db/+ and db/db at both time 











Table 13. Respiratory parameters for mitochondria isolated from control (db/+) 
and obese (db/db) mouse hearts at 10-12 weeks and 18-20 weeks of age 
10-12 weeks 18-20 weeks 
db/+ db/db db/+ db/db 
State 2 respiration 
(nmollminlmg protein) 
35.3±3.5 39.0±2.1 29.4±1.6 32.6±1.9 
State 3 respiration 
(nmollminlmg protein) 
103.9±19.1 161.6±10.6 # 144.9±9.6 165.8±9.8 
State 4 respiration 
(nmollminlmg protein) 
18.2±4.8 16.8±2.5 33.5±2.0 * 30.7±2.4 ** 
ADP/O ratio 2.2±O.1 2.4±O.l 2.5±O.O8 2.6±O.1 
Phosphorylation rate 
(nmollminlmg protein) 
307.6±19.1 392.3±36.1 363.4±28.3 435.9±32.3 
Cardiac mitochondria were isolated as described in the Materials and Methods section ofthis thesis. 

Respiration rates were determined at 25"C with malate and carnitine-L-palmitoyl (MCP) as 

substraJes. Values are expressed as mean ± S. E.M for 5-13 animals. 

/I p<0.05 compared with db/+ at 10-12 weeks. 

*p<O.OI compared with db/+ at 10-12 weeks. 
** p<O.OI compared with db/db at 10-12 weeks. 
At the 10-12 week point, state 3 respiration was significantly increased in db/db 
compared to control mice (161.6±1O.6 vs. 103.9±19.1 nmol/min/mg protein) 
(Fig. 15). However, at 18-20 weeks of age, this increase was abolished and there was 
no significant difference in state 3 respiration between the db/+ and db/db heart 
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10-12 weeks 18-20 weeks 
Figure 15. State 3 respiration rates for control (db/+) and obese (db/db) heart 
mitochondria at 10-12 weeks and 18-20 weeks of age. MCP was used as substrate. 
Respiration rates are expressed as nmol ofoxygenlminutelmg protein. 
/I p<O.05 compared with db/+ at 10-12 weeks. 
State 4 respiration was elevated at the 18-20 week time point versus the 10-12 week 
time point for the db/+ control mitochondria (33.5±2.0 vs. 18.2±4.8 nmoVrninlmg 
protein) (p<0.0 1) (Fig. 16). Likewise, state 4 respiration was increased at the 18-20 
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10-12 weeks 18-20 weeks 
Figure 16. State 4 respiration for control (db/+) and obese (db/db) heart 
mitochondria at 10-12 weeks and 18-20 weeks of age. MCP was used as substrate. State 
4 respiration represents mitochondrial oxygen consumption ajier completion ofADP phosphorylation. 
Respiration rates are expressed as nmol ofoxygenlminutelmg protein. 
* p <O.OI compared with db/+ at 10-/2 weeks. 
** p <O.OI compared with db/db at 10-/2 weeks. 
The ADP/O ratio, an index of the mitochondrial efficiency (ratio between nmol of 
ADP phosphorylated and oxygen consumed during state 3 respiration) did not differ 
at any of the time points (Fig. 17). 
• db/+ 
db/db





10-12 weeks 18-20 weeks 
Figure 17. ADP/O ratio for control (db/+) and obese (db/db) heart mitochondria 











The ADP phosphorylation rate was unchanged between the db/+ and db/db at both 
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10-12 weeks 18-20 weeks 
Figure 18. ADP phosphorylation rate in isolated heterozygous control (db/+) and 
obese (db/db) heart mitochondria at 10-12 weeks and 18-20 weeks of age. MCP 
was used as substrate. Phosphorylation rate is expressed as nmol ofADPlminutelmg protein. 
7.1.4. Histology 
To assess whether any structural alterations occurred in the obese mouse heart, we 
perfonned H&E staining analysis. However, no significant alterations were found in 





















Figure 19. Hematoxylin and eosin (H&E) st ined heart tissues. Magnification 200X. 
A) Control (db/+) and B) obese (db/db) mice at the /0-/2 weeks of age; C) Control (db/+) and D) 
obese (db/db) mice at /8-20 weeks ofage (n=6). 
We next wanted to determine if there was any intracellular lipid accumulation within 
the obese heart muscle and subsequently stained slides with OS04, used as a stain for 
lipid droplets. 107 Here, we found no histological evidence for significant lipid 
deposition in db/db mice vs. matched controls at the 10-12 week or the 18-20 week 













A. 	 B. 

c. 	 D. 
Figure 20. Osmium tetroxide (OS04) stained heart tissues. Magnifications 200X A) 
Control (db/ +) and B) obese (db/db) mice at the 10-/2 weeks ofage; C) Control (db/+) and D) obese 
(db/db) mice at 18-20 weeks ofage (n=6). 
7.2. 	 Gender-dependent changes in mitochondrial 
respiratory function 
7.2.1. Baseline metabolic characterization 
To investigate our hypothesis that females possess innate cardioprotective programs, 
we focused on the 18-20 week time point. Here, gender did not have a significant 
effect on body weight and plasma glucose levels (Table 14). Interestingly, heart 
weight and heart: body weight ratio were significantly decreased in both male and 
female db/db compared to matched controls. 
60 











Table 14. Baseline characterization of male and female heterozygous (db/+) and 












































Values are expressed as mean ± S.E.MforIO-24 animals. 
** p<O.OOI compared with age-matched heterozygous db/+ mice. 
7.2.2. Mitochondrial respiration 
We next compared cardiac mitochondrial respiratory function between male and 











Table 15. Cardiac mitochondrial respiratory function for male and female 
control (db/+) and obese (db/db) mice 
Male Female 
db/+ db/db db/+ db/db 
State 2 respiration 
(nmollminlmg protein) 29A±1.6 32.6±1.9 36.6±1.7 * 35.0±2.0 
State 3 respiration 
(nmollminlmg protein) 145.0±9.6 165.8±9.8 175.6±7.1 177.8±12.9 
State 4 respiration 
(nmollminlmg protein) 33.5±2.0 30.7±2A 38.8±1.3 36.8±1.6 
ADP/O 2.5±O.1 2.6±O.1 2.2±O.O4 2.3±O.1 ** 
Phosphorylation rate 
(nmollminlmg protein) 363A±28.3 436.0±32.3 381.0±20A 411.6±40.0 
Cardiac mitochondria were isolated as described in the Materials and Methods section ofthis thesis. 

Respiration rates were determined using MCP as substrates. 

Values are expressed as mean ± S.E.M for 7-9 animals in each group. 

• p <O.05 compared with male heterozygous db/+ mice . 
.. p <O.05 compared with male obese db/db mice. 
State 2 respiration was similar between db/+ and db/db for male mice. However, state 
2 respiration was increased for female db/+ compared to male db/+ heart 
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Figure 21. State 2 mitochondrial respiration: gender-dependent changes for 
control (db/+) and obese (db/db) heart mitochondria. MCP was used as substrate. 
Respiration rates are expressed as nmol ofoxygen/minute/mg protein. 
* p<O.05 comparedwiLh male heterozygous db/+ mice. 
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Male 	 Female 
Figure 22. State 3 mitochondrial respiration: gender-dependent changes for 
control (db/+) and obese (d b/db) heart mitochondria. MCP was used as substrate. 











Furthermore, state 4 respiration was similar between male and female db/+ and db/db 
heart mitochondria (Fig. 23). 
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Figure 23. State 4 mitochondrial respiration: gender-dependent changes for 
control (db/+) and obese (db/db) heart mitochondria. MCP was used as substrate 
Respiration rates are expressed as nmol ofoxygen/minute/mg protein. 
The ADP/O ratio was moderately but significantly reduced in the db/db female 
versus db/db male 2.6±O.1 v . 2.3±O.l (Fig. 24). 
** db/+ 










Figure 24. ADP/O ratio: gender-dependent changes for control (db/+) and obese 
(db/db) heart mitochondria. MCP was used as substrate 











ADP phosphorylation rate was unchanged between male and female db/+ and db/db 
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Figure 25. ADP phosphorylation rate: gender-dependent cbanges for control 
(db/+) and obese (db/db) heart mitochondria. MCP was used as substrate. 
Phosphorylation rates are expressed as nmol ofA DPlminuteJmg protein. 
Interestingly, state 3 mitochondrial respiration recovery in response to anoxia was 
increased in female compared to male control hearts (23.6±1.6 vs. 16.4±2.6) (p<O.05) 
















Figure 26. Percentage of state 3 respiration recovery in isolated heterozygous 
control (db/+) vs. obese (db/db) heart mitochondria. MCP was used as substrate. 
Percentage recovery of state 3 respiration was determined by measuring the oxygen uptake for 5 
minutes after 20 minutes ofanoxia. 
* p <0.05 compared with male heterozygous dbl+ mice. 











To detennine whether such improved recovery related to an increased bioenergetic 
capacity, we next measured total mitochondrial ATP levels. Here, the total cardiac 
mitochondrial ATP concentration was significantly increased in female compared to 
male control mice (39.0±2.7 vs. 26.2±2.6 IlmoUmg protein) (Fig. 27). In agreement 
with our respiration data, this effect was abolished in the obese female mouse. 
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Figure 27. Gender-dependent changes of total mitochondrial ATP in 
heterozygous control (db/+) and obese (db/db) heart mitochondria. Total 
mitochondrial ATP concentration was assayed using a luciferin-Iuciferase luminometry luminescence 
method modified from Fryer et al. (2000) 102 Concentration of the total mitochondrial ATP is 
expressed as IImol/mg protein. 
* p<0.05 compared with male heterozygous db/+ mice. 
~ U ~ p <O. 001 compared with female heterozygous db/+ mice. 
7.2.3. Histology 
To examine whether any morphological differences existed between male and female 
mouse hearts, we performed hematoxylin and eosin (H&E) and osmium tetroxide 
staining analysis. Here, we found that male and female db/+ and db/db were not 














Figure 28. Hematoxylin and eosin (H&E) stained heart tissues. Magnification 200X 
A) Male control (db/+), B) obese (db/db) mice, C) Female control (db/+) and D) obese (db/db) mice 
at /8-20 weeks ofage (n=6). 
A. B 
c. D. 
Figure 29. Osmium tetroxide (0804) stained heart tissues. Magnification 200X A) 

Male control (db/+), B) obese (db/db) mice, C) Female control (db/+) and D) obese (db/db) mice at 

/8-20 weeks ofage (n=6). 
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7.2.4. Electron microscopy 
To gain further insight into the role of the mitochondrion in the diabetic heart, we 
perfonned EM at the 10-12 and 18-20 week time points. Since no significant 
morphological (i.e. H&E staining) and lipid abnonnalities (i.e. OS04 staining) were 
found in db/+ compared to db/db mouse hearts at 10-12 and 18-20 weeks, we next 
focused on whether any mitochondrial ultrastructural changes occurred in a 
gender-dependent manner. Unfortunately, due to limited availability of db/db mice at 
10-12 weeks of age, only db/+ hearts from this age group were examined. 
At 10-12 weeks, control db/+ heart mitochondria were highly organized, the 
condensed cristae suggesting functional mitochondria with high metabolic efficiency. 
However, no visible abnonnalities were detected between male and female mouse 
























Figure 30. Electron Microscopy (EM) for male and female control (db/+) hearts 
at 10-12 weeks age. Law magnification (5000X): A) male and B) female (db/+) mice; High 
magnification (25,000X): C) male and D) female (db/+) mice at 10-12 weeks ofage (n=3). 
Although male db/+ mitochondria at 18-20 weeks displayed an organized 
mitochondrial profile, it did not display the same degree of condensed cristae like the 
earlier time point (Figs. 31 A and C). This suggests that the severity of the 
mitochondrial distortion is age dependent. 
Intriguingly, male obese db/db hearts displayed further mitochondrial ultrastructural 
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damage i.e. distorted cristae organization, lipid deposition and vacuole accumulation 
were observed (Figs. 31 B and D). 
A. B. 
c. D. 
Figure 31. Electron Microscopy (EM) for male control (db/+) and obese (db/db) 
hearts at 18-20 weeks age. Low magnification (5000X): A) male control (db/+), B) obese 
(db/db) mice; High magnifica/ion (25,OOOX): C) male control (db/+) and D) obese (db/db) mice at 
18-20 weeks ofage (n=3). 
For the females, db/+ mitochondria were well organized and the number of 












32 A and C). Unlike the controls, lipid droplets were stained in the female db/db. 
However, the degree of matrix distortion in females appeared to be reduced 
compared to age-matched male db/db (Figs. 32 B and D). This suggests a higher 
degree of mitochondrial ultrastructural changes in male versus female db/db mouse 




Figure 32. Electron Microscopy (EM) in female control (db/+) and obese (db/db) 
heart at 18-20 weeks of age. Low magnification (5000X): A) female control (db/+), B) obese 
(db/db) mice; High magnification (25,000X): C) female control (db/+) and D) obese (db/db) mice at 















Recently, we initiated a long-term study of the db/db mouse to further investigate our 
hypothesis. For the pilot study we investigated mitochondrial respiratory function 
and histological! morphological changes in db/db mice aged 55-56 weeks. 
8. 	 Pilot Study: Age- and Gender-Dependent 
Changes in a Type IT Diabetic Mouse 
Model 
8.1. 	 Baseline metabolic characterization (55-56 weeks) 
Body weight was significantly increased in obese animals, although gender did not 
have any effect (Table 16). Initially, postprandial plasma glucose levels were 
measured, but it was surprisingly low. Thereafter, we measured fasting plasma 
glucose levels to better reflect the changes in glucose levels in these animals. 
Interestingly, postprandial and fasting blood glucose levels were not significantly 
different in 55-56 week-old male and female db/db mice compared to age-matched 
controls. However, thes  values were much lower compared to earlier time points 
investigated i.e. 10-12 and 18-20 weeks. In addition, trace levels of ketone bodies in 
urine were observed using gluco/ ketone urine test strips. 
Table 16. Baseline characterization of male and female heterozygous (db/+) and 
diabetic (db/db) mice at the age of 55-56 weeks 
Body weight (g) Blood glucose Fasting blood 
(mmollL) glucose (mmollL) 
Male db/+ 26.8±O.3 7.5±O.4 6.6±O.3 
db/db 51.8±l.O § 7.2±O.7 6.1±O.5 
Female db/+ 21.9±O.2 6.8±O.3 6.2±O.2 
db/db 55.7±2.7 § 8.4±2.0 7.8±O.9 












8.2. Mitochondrial respiration 
We subsequently detennined cardiac mitochondrial respiratory function at the 55-56 
week time point (Table 17). 
Table 17. Cardiac mitochondrial respiratory function for male and female 
control (db/+) and obese (db/db) mice 
Male Female 
db/+ db/db db/+ db/db 
State 2 respiration 
(nmollminlmg protein) lO.S±l.O 2S.1±1.3 § 11.8±1.6 23.6±1.1 § 
State 3 respiration 
(nmollminlmg protein) 6 1.7±7.9 117.7± 13.3 # 60.6±8.2 lS0.5±7.S § 
State 4 respiration 
(nmollminlmg protein) 7.5±l.O 26.3±1.3 § lO.l±l.S 20.9±1.6 § 
ADP/O 3.1±O.Ol 2.3±O.2 § 2.5±O.1 2.6±O.l 
Phosphorylation rate 
(nmollminlmg protein) 194.S±2S.7 276.6±44.6 1 64.77±26.6 390.7±lO.2 § ** 
Cardiac mitochondria were isolated as described in the Materials and Methods section ofthis thesis. 

Respiration rates were determined using MCP as substrates. Values are expressed as mean ± S.E.M 

for 5-8 animals in each group. 

** p<O. 05 compared with male obese db/db mice. 

# p <O.OI compared with age-matched heterozygous db/+ mice. 

§ p <O.OOI compared with age-matched heterozygous db/+ mice 

At the 55-56 week point, state 2 respiration was significantly increased in male db/db 
(25.1±1.3 vs. 1O.5±l.O nmollminlmg protein) and female db/db (23.6±1.1 vs. 
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Figure 33. State 2 mitochondrial respiration for control (db/+) and obese (db/db) 





~ p <O.001 compared with age-matched heterozygous db/+ mice 

State 3 respiration was elevated in db/db compared to control mIce In male 
(l17.7±13.3 vs. 61.7±7.9 nmollminlmg protein) (p<O.Ol) and in female mitochondria 
(l50.5±7.5 vs. 60.6±8.2 nmollminlmg protein) (p<O.OOl) (Fig. 34). 
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Figure 34. State 3 mitochondrial respiration for control (db/+) and obese (db/db) 
heart mitochondria. MCP was used as substrate. Respiration rates are expressed as nmol of 
oxygen/min ute/mg protein. 
§ p<O.OOl compared with age-matched heterozygous db/+ mice. 











State 4 respiration was increased for male db/db (26.3±1.3 vs. 7.5±1.0 nmollminlmg 
protein) (P<O.OO 1) and for female db/db (20.9± 1.6 vs. 1 O. l± 1.5 nmollminlmg protein) 
(P<O.OO 1) compared to age-matched controls (Fig. 35). 
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Figure 35. State 4 mitochondrial respiration for control (db/+) and obese (db/db) 





~ p <O.OOI compared with age-matched heterozygous dbl + mice 

The ADP/O ratio was significantly reduced in db/db male compared to age-matched 
controls (2.3±O.2 vs. 3. I±O.Ol). However, ADP/O ratio was similar between female 











Figure 36. ADP/O ratio mitochondrial respiration for control (db/+) and obese 
(db/db) heart mitochondria. MCP was used as substrate. Respiration rates are expressed as 
nmol of oxygen/minute/mg protein. 











ADP phosphorylation rate was unchanged in male. However, female db/db 
mitochondria displayed increased ADP phosphorylation rate compared to 
age-matched db/+ control (390.7±10.2 vs. 164.77±26.6 nmollminlmg protein) 
(p<0.001). In addition, ADP phosphorylation rate in female db/db was significantly 
higher compared to male db/db (390.7±10.2 vs. 276.6±44.6 nmollminlmg protein) 
(p< 0.05) (Fig. 37). 
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Figure 37. ADP phosphorylation r ate in isolated control (db/+) and obese (db/db) 





§ p <O. 001 compared with age-matched heterozygous db/+ mice. 

** p <0.05 compared with male obese db/db mice. 

In response to 20 minutes anOXia and 5 minutes of reoxygenation, state 3 
mitochondrial respiration recovery was increased in male db/db compared to controls 
(p<0.05) (Fig. 38). However, no differences were observed between female db/+ 
































Figure 38. Percentage of state 3 respiration recovery in isolated heterozygous 
control (db/+) vs. obese (db/db) heart mitochondria. Mep was used as substrate. 
Percemage recovery of state 3 respiration was determined by measuring the oxygen uptake for 5 
minutes after 20 minutes ofanoxia. 
* p <0.05 compared with male heterozygous db/+ mice. 
8.3. Histology 
Since systemic glucose levels in the obese db/db were sequentially reduced 
compared to the earlier time points, we next examined morphological changes (H&E 
staining) in heart, liver and pancreas in order to gain more in insight into this 
phenomenon. 
Here, morphological changes were similar in male and female db/+ and db/db mice. 
No morphological changes were observed in db/+ and db/db mouse hearts. However, 
in the liver, non-alcoholic steatohepatitis (NASH) was evident as shown by increased 
TG accumulation and inflammation. Enlarged islet was observed in the db/db 
















Figure 39. Hematoxylin and eosin (H&E) stained for male heart, liver and 
pancreatic tissues at 55-56 weeks age. Magnification 200X For heart tissue A) control 
(db/+), B) obese (db/db); liver C) control (db/+), D) obese (db/db); pancreas E) control (db/+) and F) 

















Figure 40. Hematoxylin and eosin (H&E) stained for female heart, liver and 
pancreatic tissues at 55-56 weeks age. Magnification 200X For heart tissue A) control 
(db/+), B) obese (db/db); liver C) control (db/+), D) obese (db/db); pancreas E) control (db/+) and F) 
obese (db/db) mice at 55-56 weeks ofage (n=3). 
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Obesity is a major contributor to the global burden of disease. 3 Moreover, it is 
closely associated with the development of type II diabetes. 12, 13 Recent studies have 
demonstrated that obese and! or type II diabetic subjects have markedly increased 
circulating FFAs. 19,61 It has been proposed that increased FFA supply plays a major 
role in the development of insulin resistance. 58 For example, elevated FFA levels 
have been associated with metabolic abnormalities such as a reduction in PDH 
activity, glucose transport, glycogen synthesis and ATP production. 61,82 These data 
reflect impairment of carbohydrate metabolism and mitochondrial oxidative 
phosphorylation. As a result, the diabetic heart switches its substrate preference to 
high FA utilization. Moreover, ketone bodies also become a more prominent fuel 
substrate in this instance. 19 Thus, it has been proposed that metabolic remodeling by 
the diabetic heart may lead to mitochondrial and contractile dysfunction. 
In light of this, we tested the hypothesis that obesity-induced insulin resistance! type 
II diabetes, excessive FFA supply decreases mitochondrial bioenergetic capacity of 
the heart. Moreover, we hypothesized that females possess innate cardioprotective 
programs that result in enhanced mitochondrial bioenergetic capacity compared to 
males. We explored our hypothesis employing two rodent models i.e. a) a rat model 
of diet-induced obesity and b) a transgenic mouse model of obesity-induced type II 
diabetes. 
Rat Model ofDiet-Induced Obesity 
We found that body weights were significantly increased in rats fed the cafeteria diet. 















cardiac hypertrophy. This is consistent with previous work on diabetic 
Goto-Kakizaki (GK) rats. 31 Fasting plasma insulin, HbAlc, NEFA and TG levels 
were elevated in obese rats. HDL cholesterol levels were also reduced. However, 
plasma glucose levels were not significantly increased. Moreover, a glucose 
tolerance test performed by our collaborator Dr. Eugene du Toit, found no differences 
between obese and control rats. Together these data suggest that the rat model we 
employed may be considered as a model ofobesity and insulin resistance. 
We next assessed cardiac mitochondrial respiratory function in obese and control rats. 
Here, obesity did not have any effect on baseline state 3 mitochondrial respiration 
rates. Moreover, mitochondrial efficiency (ADP/O) was maintained in obese rats. 
However, ADP phosphorylation rate was.reduced in obese rats. These data therefore 
suggest reduced bioenergetic capacity in the obese rats. Mitochondria from obese rats 
displayed reduced state 4 respiration when glutamate was ~mployed as oxidative 
substrate. This may indicate improved mitochondrial coupling in the presence of 
glycolytic substrates. Also, state 2 (endogenous) respiration and ADP 
phosphorylation rate were attenuated in obese rats when malate and 
carnitine-L-palmitoyl was used as fuel substrates. This suggests impaired FA 
metabolic capacity despite sustained state 3 respiratory rates at baseline. To gain 
further insight into possible mitochondrial respiratory defects, we exposed isolated 
heart mitochondria to an acute anoxic insult followed by reoxygenation. Interestingly, 
we found that recovery of state 3 respiration was significantly impaired in heart 
mitochondria from obese rats. 
In parallel, our collaborator (Dr. du Toit) found that contractile function in these 

















Together these data show that bioenergetic capacity may be impaired in obese rats at 
baseline. Furthermore; in response to oxidative stress; there is an association between 
impaired mitochondrial respiratory function and contractile function in obese; 
insulin-resistant rats. At present, we are investigating the underlying mechanisms 
responsible for this. There are several possibilities that may explain these findings. 
However, we are of the opinion that elevated FF A supply to the diabetic heart 
may be a critical component leading to attenuated respiratory capacity and contractile 
function. We propose that in this instance, components of the mitochondrial 
respiratory chain are downreguiated. For example, Mootha et a1. 108 and Patti et al. 
(2003) 109 reported coordinate downreguiation of several nuclear-encoded 
mitochondrial genes in response to high fat exposure. Moreover, Boudina et al. 
(2005) 82 found reduced protein levels of mitochondrial respiratory chain complexes 
in a mouse model oftype II diabetes. 
Mouse Model ofObesity-Induced Type II Diabetes 
We initially set out to determine temporal changes in male mitochondrial respiratory 
function in the db/db mouse strain. Here, we found that state 3 mitochondrial 
respiration was significantly increased in the obese mouse at 10-12 weeks. However, 
there were no differences between state 2 and state 4 mitochondrial respiration rates. 
Furthermore, ADP/O and ADP phosphorylation rates were similar for obese versus 
control heart mitochondria. These data suggest that at 10-12 weeks age, thought to be 
at the metabolic syndrome stage; the respiration rate is increased but that this does 
not significantly impact on the efficiency and the rate of mitochondrial ATP 
production. Increased state 3 mitochondrial respiration rate is consistent with 
enhanced rates of ex vivo FA oxidation reported for db/db hearts at this age. 106 


















obese hearts at age 10-12 weeks. Since we found that the ADP/O ratio was 
unchanged, we propose that uncoupling of respiration may not be a factor in this 
instance. However, since we did not measure oligomyocin-induced proton leak we 
cannot totally exclude increased uncoupling associated with the higher oxygen 
consumption. To gain further insight we also attempted to measure cardiac UCP 
protein levels, but had great difficulty in optimizing the Western blotting technique 
for UCP2 and UCP3 detection. We employed different commercially available 
antibodies for UCP2 and UCP3, but the degree of non-specificity were routinely 
found to be too high to make any meaningful conclusions. 
At 18-20 weeks age, there was no difference in state 3 respiration between controls 
and obese mice. These data show that the db/+ mice had increased state 3 respiration 
in an age-dependent manner to match levels found in the obese mouse. However, 
state 3 respiration rates in obese mice were not further increased compared to the 
younger mice (10-12 weeks). This suggests that the oxidative capacity of the 18-20 
week old obese mouse may be reduced. In agreement, others reported reduced state 3 
oxidative rates in diabetic mice. no Here, it was suggested that reduced mitochondrial 
content and lower NAD+ and NADH levels were responsible for the lower state 3 
respiration rate. Consistent with the 10-12 week point, no differences were found for 
ADP/O, ADP phosphorylation rate and state 2/4 respiration rates. However, state 4 
respiration for both control and obese mitochondria were significantly increased at 
the 18-20 week point compared to the 10-12 week point. This may reflect an overall, 
age-dependent increase in uncoupled respiration. 
Aasum et al. (2003) 75 recently showed that 16-18 week old db/db hearts exhibited 
contractile dysfunction and reduced post-ischemic recovery of function. To further 
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assess mitochondrial respiratory capacity in the db/db hearts, we exposed isolated 
mitochondria to an anoxic insult followed by reoxygenation and determined state 3 
respiration rates. However, recovery of state 3 respiration was not different between 
control and obese mitochondria. We subsequently investigated whether there were 
any ultrastructural changes between control and obese hearts at the 18-20 week point. 
Here, we found no major differences between these hearts. Moreover, histological 
analysis showed no significant increase in lipid deposition in obese hearts. 
We next performed EM analysis of heart tissues to examme whether the 
ultrastructure of obese mouse mitochondria was intact. Here, obese hearts displayed 
mitochondrial ultrastructural damage Le. distorted cristae organization, lipid 
deposition and vacuole accumulation. Similar observations were found in db/db 
ovarian tissues III and in skeletal muscle of type II diabetic patients. 112 We propose 
that changes in mitochondrial ultrastructure may be responsible for obese mice not 
being able to further increase respiratory capacity to deal with increased FF A supply. 
We therefore speculate that increased FA uptake may exceed FA oxidation capacity 
thereby resulting in intracellular lipid accumulation in 18-20 week-old diabetic hearts. 
Our data are consistent with previous studies investigating mitochondrial 
ultrastructure in the diabetic heart. For example, Hsaio et al. (1987) 113 found lipid 
accumulation and glycogen granules around diabetic mitochondria. In agreement, 
Shen et al. (2004) 114 reported severe damage to mitochondria oftype I diabetic mice. 
Moreover, Morinho et al. (2005) us found reduced mitochondrial content in skeletal 
muscle of type II diabetic patients, suggesting that this would lead to impaired FA 
oxidation and therefore intracellular lipid accumulation. Increased intracellular lipid 
accumulation is thought to result in apoptosis via a ceramide-induced signaling 













components. In support, Kanazawa et al. (2002) 116 found reduced expression of 
cytochrome b and ATP synthase subunits in diabetic rat hearts. Moreover, previous 
workers reported reduced expression of nuclear-encoded mitochondrial genes in 
response to high fat exposure. 108, 109 Therefore, a reduction in mitochondrial 
respiratory chain components together with damaged mitochondria may contribute to 
the diabetic heart's inability to increase respiratory capacity. In addition, other 
non-metabolic mechanisms including alterations in calcium handling could also 
contribute to the change in cardiac function in diabetes. 
Gender-dependent Changes in Mitochondrial Respiratory Function 
Heart failure appears to be less common and less severe especially in young 
females. 23, 117 Human and animal studies show that young females display more 
favorable cardiac adaptation in several experimental and clinical conditions. 117 
However, the precise mechanisms underlying this protection are unclear. 
Our results indicate no significant differences in mitochondrial respiration for female 
control and obese mitochondria (18-20 weeks of age). When comparing male with 
female respiratory function, we found that state 2 respiration was significantly higher 
in female controls. We also found that female controls displayed less mitochondrial 
ultrastructural damage compared to males. Together these data suggest that females 
possess a protective phenotype at baseline. To further investigate male and female 
differences, we subjected these mitochondria to an oxidative stress i.e. 
anoxia-reoxygenation. Here, we found that female controls showed improved state 3 
mitochondrial respiration recovery compared to male controls. In agreement, 
mitochondrial ATP levels were significantly increased in female compared to male 
controls. Together our respiration data suggest that females have increased 
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bioenergetic capacity at baseline that protects against external stresses. 
The precise mechanisms underlying this protective phenotype in females are unclear. 
However, previous studies indicate that this may be due to several factors 
e.g. estrogens, 1I8 higher intrinsic HDL cholesterol content, 91 activation of 
anti-apoptotic mechanisms 117 and augmented antioxidant ability 93,119 in young 
females compared to male and postmenopausal females. 120 For example, estrogen 
has been found to increase "good cholesterol" i.e. HDL 92, lower VLDLI TG ratio 
and lower "bad cholesterol" i.e. LDL by increasing its clearance. 91 Furthermore, 
females possess higher HDL levels compared to males, with levels remaining steady 
throughout their lives. 91 
Others have suggested that altered MAP kinase pathways may play a role in 
gender-related cardioprotection. For example, Wang et al. (2006) 118 demonstrated 
increased ERK activation in females suggesting that such activation of MAP kinase 
pathways may mediate gender-related protection. Moreover, they also proposed that 
activated ERK may mediate the antioxidant effects of estrogens. Here, ERK 
activation activated the transcriptional regulator NF-KB, which in tum induced 
superoxide dismutase (SOD) and glutathione peroxidase (GPx) gene expression. 118 
Lower free· radical production observed in female mice may therefore reflect 
increased SOD and GPx expression. Furthermore, estrogens also increase the 
expression and activity of AktI PKB 120 thereby providing a further rationale for 
increased resistance of females to myocardial apoptosis 117 In addition, others have 
shown that female rat hearts showed improved recovery in response to 
ischemia-reperfusion. 121 Here, the authors found increased activation of Akt and 
















that increased antioxidant capacity and hence reduced ROS production may result in 
improved recovery in mitochondrial respiratory function in female mice in response 
to oxidative stress. 
Interestingly, we found that the augmented bioenergetic capacity observed in female 
controls at baseline was abolished with obesity. Here, obese female mice displayed 
similar rates of recovery as males in response to anoxia-reoxygenation. Moreover, 
mitochondrial ATP levels were also significantly reduced in obese females. We are 
currently investigating whether signaling pathways (e.g. Akt and PKCs) and! or 
expression of mitochondrial respiratory chain components are reduced in obese 
female mice. 
Since it is thought that especially younger females are protected from CVD, 120, 122, 
123 we initiated a pilot study to investigate older db/db mice (55-56 weeks) to further 
assess age- and gender-dependent changes in mitochondrial respiration. 
Pilot Study: Age- and Gender-Dependent Changes in Type II Diabetic 
Mouse Model (55-56 weeks) 
To the best of my knowledge, this is the first attempt to characterize db/db mice at a 
much later age (55-56 weeks). Here, state 2, 3 and 4 mitochondrial respiration were 
significantly reduced in both male and female controls compared to mice aged 18-20 
weeks. We propose that this overall reduction in mitochondrial respiratory function is 
an age-dependent effect i.e. this may be due to increased ROS production due to 
aging. 124, 125 It has been reported that elevated ROS levels may lead to a number of 
events, including increased mitochondrial DNA mutations that may contribute to 














Surprisingly, we found that 55-56 week old obese mice displayed increased state 2, 3 
and 4 mitochondrial respiration versus controls, matching levels observed in the 
18-20 week-old mitochondria. This effect was paralleled by the ADP 
phosphorylation rate. Also, 55-56 week old obese males showed improved recovery 
in response to anoxia-reoxygenation. These data suggest that the earlier effects or 
obesity on mitochondrial respiration (i.e. at 10-12 weeks and 18-20 weeks) are 
compensated for by the older obese mice, especially the obese males. In agreement, 
no ultrastructural changes were observed for obese heart tissues in mice aged 55-56 
weeks. However, significant lipid depositions were found in the liver accompanied 
by hypertrophy of pancreatic p-cells. Despite the contractile dysfunction reported at 
the 16-18 week point, 75 we found that obese diabetic mice survived reasonably well 
up to the 55-56 week point. We therefore speculate that age-dependent compensatory 
mechanisms are induced to ensure maintenance of cardiac contractility in these 
animals. It is likely that protective mechanisms activated by obese males may be 
independent ofchanges in mitochondrial bioenergetic capacity. 
As indicated earlier, this was a first attempt to use older animals (55-56 weeks). Due 
to a limited animal availability, it is difficult to speculate why the glucose levels 
returned to normal. However, lipid deposition may be oversaturated in the liver 
thereby affecting its normal function i.e. leading to a reduction in hepatic 
gluconeogenesis and reduced plasma glucose levels. Furthermore, I propose that 
/3-cell enlargement forms part of a compensatory process (early on during diabetic 
phenotype) to increase the release of insulin in order to deal with the high level of 
glucose in diabetes. This process is probably irreversible, hence a situation may arise 
during late diabetes where /3 -cells are enlarged while plasma glucose levels are low. 


















We have detennined cardiac mitochondrial respiratory function in rodent models of 
obesity and obesity-induced type II diabetes. Our data show that mitochondrial 
respiratory capacity is impaired in obese rats when stressed. We speculate that this 
may be due to reduced expression of mitochondrial respiratory chain complexes in 
the diabetic heart. For the mouse model of type II diabetes we found increased 
respiratory capacity at 10-12 weeks, with no evidence of oxygen wastage or 
reduction of respiratory capacity. However, 18-20 week-old obese mice were unable 
to further increase respiratory capacity. We also found increased mitochondrial 
ultrastructural damage and intracellular lipid accumulation in these diabetic hearts. 
We speculated that lipid accumulation occurs as a result of a mismatch between 
increased FA uptake and decreased FA oxidative capacity. However, FA uptake and 
FA oxidation need to be measured to confirm this. Mitochondrial respiratory function 
in the two models was different and it could be due to species-specific differences 
since the genetic make up of the two models was different. Hence, this may have 
lead to variation in mitochondrial function. Also, obesity in the two models was 
induced either genetically or by diet manipulation. This plays an important role 
regarding the impact on mitochondrial respiratory function. 
We also found interesting gender-dependent changes Le. younger female mice 
showed enhanced protection when mitochondria were stressed by 
anoxia-reoxygenation. These data were paralleled by increased mitochondrial ATP 
levels, suggesting that young female mice possess increased mitochondrial 
bioenergetic capacity at baseline. Moreover, our EM data suggest that the 
ultrastructure of male mitochondria is more disorganized when compared to females 












mice at baseline is abolished with obesity. 
At the later age (55-56 weeks), mitochondrial respiratory function and bioenergetic 
capacity is reduced in both male and female mice at baseline. We suggest that this is 
an age-dependent phenomenon and speculate that it may be caused by a number of 
factors, including increased ROS production. Surprisingly, we found that older, obese 
males and females induced compensatory mechanisms to deal with the chronic 
diabetic mileu. Here, mitochondrial respiratory function was increased, reaching 
levels observed in younger mice (18-20 weeks). Together, this study highlights the 
significance of sustained biogenetic capacity to ensure an organism's survival. 
However, with obesity and obesity-induced type II diabetes mitochondrial energetic 
homeostasis is perturbed, and we speculate that this may eventually impact o~ the 
heart's contractile function. Our data suggest that therapeutic interventions aimed at 
enhancing mitochondrial energy homeostasis may improve the diabetic heart's 
function and therefore help to alleviate the increasing burden of disease of 













The homozygous mutants of the db/db (BK8.Cg-m+I+Leprdb/J) strain are sterile. 94 
Propagation of this strain therefore mainly depends on the availability of 
heterozygous (db/+) mice. According to Mendelian law, there should be 1: 2: 1 ratio 
of obtaining homozygous obese animals. However, the breeding period was longer 
than what we expected and only a few offspring were produced, especially the obese 
db/db. There's abnormality in the sexual organ of the female db/db which leads to 
sterility of the homozygous mutant. However, the heterozygous female is 
phenotypically normal and generally used in breeding. It is possible that the 
heterozygous female has lower estrogen levels than normal thus resulting in few 
offspring produced. The lack of animal numbers therefore represented a major 
challenge to complete the current study. As a result, mice used for the 10-12 and the 
55-56 week studies were bred in-house at the Animal Unit of the University ofCape 
Town's Faculty of Health Sciences. For the 18-20 week study, we purchased mice 
directly from The Jackson Laboratory (Bar Harbor, Maine). 
High-quality mitochondrial yield is dependent on the process of mitochondrial 
isolation since any delays would affect the respiratory function. Arrested hearts with 
the last pumping of oxygen may affect the oxygen content in the cells and the 
consumption by the mitochondria Thus, mitochondrial yield! g heart weight and 
some of the basal characterization for e.g. heart dry weight was not measured. In 
addition, during the process ofmitochondrial isolation, even a gentle homogenization 
may result in mitochondrial damage (including the rupture of the mitochondrial 
membrane). Thus, such ruptured mitochondria might be misinterpreted and 















tum may lead to an incorrect association of mitochondrial damage to the degree of 
diabetes. In light of this, EM was performed only on cross sections of heart tissue 
and not on isolated mitochondria. 
The heterozygous mice (db/+) used in this project are described to be phenotypically 
normal 94 and is widely used as a control to compare with its obese counterpart. In 
light of the breeding difficulties we faced, we therefore used db/+ as controls. 
However, it would be more appropriate to include the donor strains (C57BLKS and 
DBAlJ) as positive controls. 
We did not succeed to measure UCP2 and UCP3 gene and protein levels in this study. 
I had numerous attempts at Western blotting but did not manage to optimize the 
protocol. Recently, we have learnt from others in the field that new antibodies have 
been developed for UCP2 and UCP3. We are planning to purchase these antibodies 















11. Future Studies 
We are currently performing a gene expression study (on collected heart tissues) to 
determine expression levels of several FA and glucose metabolic genes. Also, we are 
planning to measure gene expression levels of mitochondrial respiratory chain 
components. We will subsequently perform Western blotting to confIrm that protein 
levels match the gene data generated. 
For the gene study, we intend to measure Akt and PKCs phosphorylation states 
(Western blotting) to assess whether these pathways are activated in females at 
baseline and attenuated with obesity. We plan to measure ROS production for all the 
time points by measuring catalase and SOD activities (indirect measurement). 
Furthermore, cardiac function will be performed at the 55-56 week-old point (in 
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14. APpendix] " 





Animal chow I 
Water I 
Full cream condensed milk 

Sugar . ,j . 

Animal chow was soaked in water for 2 hours. Mixed all ingredients and kept at 4 C. 
. ·1 
2. Mitochondrial Isolation for Diet-Induced Rat Model 





Incubation buffer [PH7.4 J 

10 mM Tris-HCl 

250 mM sucrose 

8.5 mM KH2P04 
I 
. 3. Mitochondrial Isolation for Obesity-Induced lYPe n diabetic Mouse Model 





I, Incubation buffer [PH7.4] 

25 mM Tris-HCI 

250 mM sucrose 

8.5 mM KH2P04 
4. Lowry Protein Ass~y 
I·, . 
Solution A (CTC reagent) ~ equiil volume ofeach of the following: 
, I 
I) 20%w/v Na2C03; 0.2% w/v CuS04.5H20 and O.4%w/v K2 tartrate 
2) 10% SDS . ' , f" " . '. 
3)0.1MNaOH 
Solution B 











6. Prepare the grid: 





Stain with heavy metals-Uranyl acetate and Lead nitrate 
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